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The placenta is a transient organ that is critical for the growth and development 
of the mammalian embryo. Placental insufficiencies can lead to preeclampsia in the 
mother and intra-uterine growth restriction of the fetus. Insults incurred in utero have 
been associated with increased susceptibility to cardiovascular disease and diabetes in 
adulthood. A functional placenta develops through a delicate interplay of its vascular 
and trophoblast compartments. However, the genetic basis of trophoblast development 
and placental angiogenesis is not completely understood.  In this thesis, using a mouse 
model, I have studied the role of a micro-RNA, miR-126, in placental development. 
Additionally, I also uncovered a novel role for miR-126 in regulating glucose 
homeostasis in adults. 
The first set of studies elucidates the role of miR-126 in the murine placenta. 
Here, I determined the role of miR-126 in placental development, using a mouse 
model with a targeted deletion of miR-126. miR-126 has a novel expression domain in 
trophoblast stem cells and differentiated trophoblast sub-types in the placenta. Loss of 
miR-126 leads to significant hyperplasia in the junctional zone at embryonic day 15.5 
(E15.5) at the expense of the labyrinth, resulting in reduced placental volume for 
nutrient exchange and intra-uterine growth restriction of the embryos. Junctional zone 
hyperplasia results from increased numbers of proliferating glycogen trophoblast 
progenitors at E13.5 that give rise to an expanded glycogen trophoblast population at 
	E15.5. I also demonstrate that miR-126-/- placentas display aberrant expression of 
imprinted genes with important roles in glycogen trophoblasts and junctional zone 
development, including Igf2, H19, and Cdkn1c. Abnormal imprinted gene expression 
is restricted to the placenta and is accompanied by aberrant DNA methylation at 
imprint control centers. miR-126-/- placentas also display abnormal expression of the 
imprinting regulator, Dnmt1, through early and mid-gestation and display changes in 
global methylation at mid-gestation. Collectively, using a miR-126 loss of function 
mouse model, I have identified a novel role for miR-126 in regulating DNA 
methylation, imprinted gene expression and glycogen trophoblast proliferation in the 
placenta. 
The second set of studies focused on the role of miR-126 in glucose 
metabolism. A number of rare autosomal dominant, monogenic forms of diabetes 
termed maturity onset diabetes (MODY) have been identified in humans. miR-126+/- 
adult mice display fasting hyperglycemia and hypoinsulinemia. miR-126+/- male mice, 
but not female mice display sporadic weight-gain defects and severe glucose 
intolerance during a glucose tolerance test. This indicates that loss of even a single 
copy of miR-126 is associated with metabolic dysfunction thereby highlighting its 
importance in maintaining glucose homeostasis. 
Collectively, my studies uncovered a novel role for miR-126 in regulating 
DNA methylation and extra-embryonic energy stores in the placenta. In addition, my 
studies uncovered a potential novel role for miR-126 in regulating glucose 
homeostasis in adult mice. 
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Chapter 1- Introduction 
 
1.1 Placenta – Structure and function 
 
The placenta is a transient organ that is critical for the survival and growth of 
mammalian embryos. The placenta forms the interface between maternal and fetal 
circulations, facilitating exchange of nutrients and gases and disposal of fetal waste. It 
is a major endocrine organ, secreting hormones critical for maternal physiology during 
pregnancy and fetal growth during gestation. The placenta also forms the immune 
barrier for the fetus from the maternal immune system (Rossant and Cross 2001). 
 
A fully developed human placenta is composed of three layers: the maternal 
decidua, containing maternal vessels that bring blood to and from the implantation 
site, a middle basal zone, mainly containing trophoblasts that invade maternal vessels 
to remodel maternal arteries, and a fetal labyrinth layer containing highly branched 
villous structures of the fetal endothelium which is the site for nutrient, gas and waste 
exchange (Maltepe et al. 2010). 
 
Placental dysfunction can lead to pregnancy complications such as 
preeclampsia (PE) and intra uterine growth restriction (IUGR) that increases chances 
of morbidity and mortality in the mother and the fetus (Rossant and Cross 2001; 
Maltepe et al. 2010). PE is the leading cause of maternal and fetal morbidity and 
mortality and is characterized by the sudden onset of maternal hypertension and 
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proteinuria after 20 weeks gestation. The only treatment for PE is delivery of the fetus 
(Young et al. 2010). Placental dysfunction is also seen as the leading cause for 
increase in pre-term deliveries and growth-restricted infants in the past two decades 
(Goldenberg et al. 2008; Simmons et al. 2010). Infants from induced deliveries are 
more likely to develop complications like pulmonary dysplasia, hypertension and 
cerebral palsy. This has resulted in an increase in the number of infants admitted to 
intensive care nurseries, placing enormous emotional and economic demands on the 
society (Eichenwald and Stark 2008).  
 
Through a process called fetal programing, environmental insults incurred in 
utero can also result in an increased susceptibility to cardiovascular disease and 
diabetes later in life (Murphy et al. 2006). Although there have been improvements in 
neonatal care, early diagnosis and prevention of placental pathologies will have the 
greatest long-term impact on health care. Studying placental pathologies like 
preeclampsia and intra-uterine growth restriction requires a thorough understanding of 
the interplay between transcriptional and epigenetic regulators for human placental 
development and the effects of environment cues on these processes. 
 
1.2 Models of placental development 
 
Human placental development has mostly been studied from analysis on the 
placenta after delivery or following termination of pregnancy (Maltepe et al. 2010). A 
number of functional studies have relied on transformed human trophoblast cell lines 
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or ex vivo culture of primary trophoblasts. Several large and small animal models have 
been extremely beneficial in understanding key features of placental development in 
vivo (Rossant and Cross 2001; Maltepe et al. 2010). 
 
Placentas can be categorized based on morphology and histology. By gross 
morphology, placentas can be categorized into three distinct types: diffuse (horses, 
pigs), multicotyledonary (ruminants), zonary (carnivores) and discoid/bidiscoid 
(rabbits, primates, rodents) (Furukawa et al. 2014). A more functional characterization 
is based on histology: epitheliochorial (horses, pigs and ruminants), endotheliochorial 
(carnivores) and hemochorial (rabbits, rodents, primates) (Furukawa et al. 2014). Mice 
and humans have hemochorial placentas, with the trophoblasts directly in contact with 
maternal blood (Watson and Cross 2005; Maltepe et al. 2010). Although human and 
murine placentas have minor differences, both species have similar placental 
structures and are thought to share molecular mechanisms that control placental 
development (Watson and Cross 2005). Powerful genetic tools have enabled the use of 
murine models to study the roles of a single gene or combinations of gene networks in 
placental development. This has been particularly important in identifying targeted 
mutations associated with placental defects resulting in embryonic lethality. Mouse 
mutants have been used to identify several key genes for placental development. 
Genes such as Cdx2, Eomes, Esrrb, that critical for trophoblast stem cell specification 
and differentiation (Chawengsaksophak et al. 1997; Luo et al. 1997; Riley et al. 1998; 
Russ et al. 2000), Ets2, critical for ectoplacental cone fusion (Yamamoto et al. 1998), 
Bmp5, Bmp7, Vcam1, critical for chorioallantoic fusion (Li et al. 1992; Gurtner et al. 
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1995; Solloway and Robertson 1999), Gcm1, Fgfr2, PPARγ for branching 
morphogenesis and labyrinth development (Xu et al. 1998; Barak et al. 1999; Giroux 
et al. 1999; Anson-Cartwright et al. 2000), Ascl2, H19, Hectd1, for endocrine 
trophoblast maintenance (Constancia et al. 2002; Esquiliano et al. 2009; Sarkar et al. 
2014) and Igf2, Gjb2 for nutrient transport (Gabriel et al. 1998; Liang et al. 2010). 
These studies have also highlighted the importance of signaling interactions between 
the trophoblasts, the fetal vasculature and the maternal vasculature during placental 
development. 
 
1.3 Murine placental development 
 
Placental development begins at embryonic day 3.5 (E3.5) in the blastocyst 
when two distinct cell lineages are formed. The outer layer of cells called the 
trophectoderm are polarized epithelial-like cells with apical microvilli and asymmetric 
distribution of adherens and tight junctions. The inner cluster of non-polarized cells 
forms the inner cell mass (ICM) (Rossant and Cross 2001). The trophectodermal layer 
is specified through a cascade of transcription factors via the hippo-signaling pathway 
(Watson and Cross 2005). At E4.5, the trophectodermal cells not in contact with the 
ICM (mural trophectoderm) differentiate into primary trophoblast giant cells (TGCs). 
Primary TGCs undergo endoreduplication to become polyploid cells and are 
analogous to human extravillous cytotrophoblasts (Maltepe et al. 2010). From the 
polar trophectoderm (cells adjacent to the ICM), two cell layers are formed, the extra 
embryonic ectoderm (ExE) and the ectoplacental cone (EPC). The extraembryonic 
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ectoderm differentiates into trophoblasts that form the chorion and the labyrinth at 
later stages (Watson and Cross 2005; Maltepe et al. 2010). Around E8.5, the allantois 
arising from the posterior end of the mesoderm makes contact with the chorion in a 
process termed chorio-allantoic fusion (Figure 1.1). Hours after chorio-allantoic fusion 
takes place, feto-placental blood vessels invade from the allantois and undergo 
branching morphogenesis to form the fetal part of the placental vasculature (Watson 
and Cross 2005) (Figure 1.1). In mice, two layers of syncytiotrophoblast are in direct 
apposition to endothelial cells of the fetal vessels. In the human placenta, the fetal 
vasculature is in apposition to a monolayer of syncytiotrophoblasts (Maltepe et al. 
2010).  
 
Progenitors from ExE and EPC give rise to a wave of postmitotic and 
polyploid secondary TGCs. The murine placenta has four different secondary TGC 
subtypes that can be distinguished by their gene expression and location. Spiral artery 
TGCs (SpA TGCs) invade maternal arteries and replace endothelial cells through a 
process called spiral artery remodeling and vascular mimicry, resulting in dilation of 
the arteries (Adamson et al. 2002). Spiral arteries converge to form large canals, lined 
by canal TGCs (C-TGC), that carry oxygenated blood to the placental labyrinth. The 
maternal vascular spaces in the labyrinth are lined by sinusoidal TGCs (S-TGCs). 
After nutrient and waste exchange, blood moves to large lacunae lined by parietal 
TGCs that connect with the uterine veins (Simmons et al. 2007). 
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The ectoplacental cone differentiates into several cell types of the junctional 
zone and some giant cell subtypes. The junctional zone (basal zone in humans) 
anchors the fetal labyrinth to the maternal decidua and is also a major source of 
several prolactin and placental lactogens critical for maternal health during gestation 
(Simmons et al. 2008). Although the function of the junctional zone has not been 
clearly elucidated, increasing evidence from mouse mutants have highlighted the 
importance of the junctional zone and the hormones secreted by this layer (Coan et al. 
2006; John 2017). The junctional zone contains three major trophoblast subtypes- 
spongiotrophoblasts, secondary TGCs and glycogen trophoblasts. All trophoblasts 
subtypes of the junctional zone secrete a number of prolactin and placental lactogen 
hormones critical for maternal health and metabolic function during gestation (Rossant 
and Cross 2001). During late gestation, the glycogen trophoblasts migrate into the 
decidua and release glycogen into the maternal bloodstream. The function of glycogen 
trophoblasts has not been established. They are speculated to play a role in supporting 
embryonic growth during late gestation or in parturition (Coan et al. 2006). In human 
placentas, data suggests that placental glycogen is a defining feature of fetal growth 
restriction and fetal overgrowth (Akison et al. 2017). Development and differentiation 
of all the trophoblast lineages rely on a coordinated action of transcriptional, 
epigenetic and physiological factors in the placenta. 
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Figure 1.1 Overview of murine placental development 
Adapted from Rossant and Cross (2005) Physiology 20:180-193 
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1.4 Epigenetic mechanisms- Genomic imprinting 
 
Epigenetic mechanisms involve heritable changes in somatic cells that are 
independent of changes in nucleotide sequences. DNA methylation at the CpG 
dinucleotides and histone modifications represent the two major epigenetic marks that 
control the accessibility of various transcription factors to genes, promoters and 
enhancers (Jaenisch and Bird 2003). 
 
Genomic imprinting is an epigenetic modification that restricts expression of a 
gene to one of the two parental alleles. Over a hundred protein-coding genes that play 
critical roles in growth, development and behavior are imprinted in humans and mice 
(Morison et al. 2005; Peters 2014). Genomic imprinting does not represent repression 
of gene expression, but can regulate allelic expression by controlling the promoter, 
enhancer, splicing junctions and polyadenylation sites (Ferguson-Smith 2011). 
Imprinted genes appear in clusters spanning several kilobases or megabases in size 
(Wan and Bartolomei 2008; Sanli and Feil 2015). A large majority of imprinting 
clusters are also accompanied by long non-coding RNAs (lncRNAs) (Barlow and 
Bartolomei 2014). Imprinting clusters are controlled by CpG dinucleotides rich 
imprint control regions (ICR). ICRs carry parent-of origin specific methylation marks 
acquired during gametogenesis and maintained throughout development. The 
methylation imprint is established on one parental chromosome and controls 
expression of some or all imprinted genes in the cluster (Barlow and Bartolomei 2014; 
Sanli and Feil 2015). 
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DNA methylation is acquired by de novo methyl transferases and maintained 
by maintenance methyl transferases (Li et al. 1993). In the male germline, paternal 
specific methylation is acquired in prospermatogonia prior to meiosis (Lucifero et al. 
2002). In oocytes, ICRs are methylated at different times during maturation (Koerner 
et al. 2012). The coordinated action of the de novo methyltransferase DNMT3A and a 
non-catalytic protein DNMT3L is necessary for placing methylation imprints at ICRs 
(Cheng and Blumenthal 2010). Methylation at these loci is maintained by the 
maintenance methyltransferase DNMT1 (Li et al. 1993). DNMT1 catalyzes 
methylation of hemi-methylated CpG nucleotides at differentially methylated regions 
(DMRs) of ICRs during cell division (Messerschmidt et al. 2014). Apart from the 5-
methyl cytosine, various other proteins and histone modifications are also involved in 
the maintenance of imprints in somatic cells (Barlow and Bartolomei 2014). KRAB-
domain zinc finger protein ZFP57 is one such protein that recruits KAP1, which in 
turn mediates recruitment of H3-lysine 9 specific histone modifying enzymes 
(Hirasawa and Feil 2008; Quenneville et al. 2011). ZFP57 mutations in humans are 
associated with transient neonatal diabetes caused by the loss of DNA methylation at 
the PLAGL1 gene (Mackay et al. 2008). 
 
After fertilization, despite a massive wave of de-methylation, parental specific 
imprints are maintained in the inner cell mass and the trophectoderm of blastocysts 
(Reik et al. 2001; Duffie and Bourc'his 2013). The maintenance of methylation at 
ICRs is linked to patterns of histone methylation (Kelsey and Feil 2013). Histones at 
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the DNA methylated alleles of ICRs are marked by histone H3 lysine-9 trimethylation 
(H3K9me3), H3 lysine-64 tri-methylation (H3K64me3), H4 lysine-20 trimethylation 
(H4K20me3) and H4 arginine-3 dimethylation (H4R3me2s), and interact with DNA 
bound heterochromatinprotein-1 gamma (Delaval et al. 2007; Pannetier et al. 2008; 
Girardot et al. 2014). Throughout development, DNMT1 maintains imprints in 
dividing cells by catalyzing methylation of hemi-methylated CpG nucleotides at 
DMRs. 
 
The imprinting cycle is completed by erasure of imprints in primordial germ cells 
of the early embryo, by passive demethylation (failure to undergo maintenance 
methylation after DNA replication) or active demethylation, in part through the action 
of ten-eleven translocation (TET) proteins (Tan and Shi 2012; Li and Zhang 2014). 
 
1.5 Roles of imprinted genes during embryonic and placental growth 
 
A large subset of imprinted genes code for factors that regulate embryonic and 
neonatal growth (Barlow and Bartolomei 2014). Genomic imprinting is thought have 
evolved through a mechanism termed ‘parental-conflict hypothesis’. The genome of a 
developing embryo comes from two parents, but embryonic growth and nutrition is 
reliant on one parent. Paternally expressed genes are proposed to promote embryonic 
growth and maximize the fitness of an individual embryo. Maternally expressed 
imprinted genes are proposed to suppress fetal growth ensuring a more equal 
distribution of maternal resources to all offspring (Moore and Haig 1991). In support 
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of this hypothesis, a number of studies in transgenic mice with altered expression of 
imprinted genes have display abnormalities in fetal growth, placental development, 
maternal lactation and behavior and thermogenesis (Barlow and Bartolomei 2014; 
John 2017). 
 
Deletion of Igf2, a maternally imprinted gene, results in IUGR of the embryos 
and placentas at mid-gestation (E12.5) and mutant pups are born at 60% of the weight 
of wild type littermates (DeChiara et al. 1990; DeChiara et al. 1991). Placental defects 
were shown to be the primary cause of IUGR in the embryos by deleting the promoter 
of a placental-specific Igf2 transcript (Constancia et al. 2002). Both global and 
placental specific deletion of Igf2 also results in reduced numbers of glycogen 
trophoblasts in the placenta and reduced nutrient transfer to the embryo (Lopez et al. 
1996; Constancia et al. 2002; Sferruzzi-Perri et al. 2011). Biallelic expression of Igf2 
by deletion of the H19 DMR region results in increased weights of the embryos and 
placentas and an increase in the glycogen trophoblasts of the placenta (Esquiliano et 
al. 2009). 
 
Deletion of a paternally imprinted gene Cdkn1C results in overgrowth of 
embryos at E15.5 and E18.5, but do not maintain their growth trajectory to birth due to 
placental insufficiencies (Tunster et al. 2011). Apart from widespread labyrinth zone 
defects, mutant placentas also display defective maturation of glycogen trophoblast 
progenitors (Coan et al. 2006; Tunster et al. 2011). 
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Functional studies have also revealed key roles for several placental-specific 
imprinted genes in nutrient transport, growth and placental hormone expression by 
regulating the size of the placental endocrine compartment. 
 
During development, Phlda2 is mainly expressed by the placenta. Loss-of-
function, gain of function and loss of imprinting mutations have shown that Phlda2 
plays a key role in placental growth. Loss of Phlda2 results in placental overgrowth 
and hypertrophy of the spongiotrophoblast layer (endocrine compartment), resulting in 
reduced labyrinth compartment and fetal IUGR (Fitzpatrick et al. 2002; Tunster et al. 
2010). 
 
The importance of genomic imprinting is highlighted in imprinting disorders 
observed in humans. Imprinting disorders have diverse sets of clinical phenotypes, but 
primarily involve growth and neurological development. The two most well 
characterized growth disorders associated with aberrant imprinting are Beckwith–
Wiedemann (BWS) and Silver-Russell syndrome (SRS). 
 
The clinical features of BWS include prenatal and/or postnatal overgrowth, 
placental overgrowth, macroglossia (enlarged tongue), abdominal wall defects, 
hypoglycemia, renal abnormalities and predisposition to Wilm’s tumors (Maher and 
Reik 2000; Choufani et al. 2010). BWS has an estimated prevalence of one in 13,700 
live births, although cases with subtle phenotypes are thought to go undiagnosed 
(Engstrom et al. 1988; Gicquel et al. 2005). About 85% of BWS cases are associated 
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with imprinting defects at 11p15.5 (Li et al. 1998). Around 50% of these cases are 
associated with hypomethylation at the KvDMR1 locus resulting in decreased 
concentration of CDKN1C, a growth inhibitor, and 5% are associated with 
hypermethylation at the H19 DMR resulting in increased IGF2 concentrations, a 
growth promoter. A majority of BWS cases are sporadic, but approximately 15% are 
familial, 40% of which are associated with CDKN1C mutations and 20% involving 
both KCNQ1 and H19 clusters (Catchpoole et al. 1997; Choufani et al. 2010). 
 
SRS is characterized by prenatal and/or postnatal growth restriction 
accompanied by small triangular shaped face and skeletal asymmetry. The incidence 
of SRS is around one in 30000 to 100000, although minor forms are speculated to go 
undiagnosed (Hitchins et al. 2001; Abu-Amero et al. 2008). About 35-65% of SRS 
cases have been linked to hypomethylation of the H19 DMR, resulting in bi-allelic 
expression of H19/IGF2 and reduced concentrations of IGF2 and 10% cases resulting 
from maternal uniparental duplications on chromosome 7. Several SRS patients with 
hypomethylation at the H19 DMR also exhibit methylation defects at multiple 
imprinted loci, which is suggestive of a defect in imprint maintenance post fertilization 
(Azzi et al. 2009; Begemann et al. 2011; Kannenberg et al. 2012). 
 
Several gene expression studies on the global transcriptome in IUGR placentas 
have demonstrated upregulation of imprinted genes like Phlda2, Peg3, Peg10 and 
Plagl1 (Abu-Amero et al. 1998; McMinn et al. 2006; Diplas et al. 2009; Piedrahita 
2011; Kumar et al. 2012). Consistent results from multiple studies suggest that 
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imprinted genes are closely associated with the etiology of IUGR in humans. 
 
1.6 Assisted reproductive technologies and imprinting disorders 
 
Assisted reproductive technology (ART) can be described as manipulation of one 
or several steps of conception. ART can include the use of hormones to stimulate the 
ovary for supernumerary oocyte production, in vitro oocyte maturation, 
intracytoplasmic sperm injection, and in vitro culture of pre implantation embryos and 
cryopreservation of gametes or embryos. Although ART has been a boon for couples 
with compromised fertility to conceive children, it has also been associated with 
IUGR, abnormal placentation and increased risk for imprinting disorders. 
 
Although the effect of ART on imprinting has not been well studied in humans, 
studies in cattle and sheep born after in vitro culture of embryos revealed a high 
incidence of high birth weight, neonatal respiratory distress, skeletal abnormalities and 
increased incidence of infant death (Young et al. 1998). Mouse models of ART 
demonstrate that the procedures affect embryonic development, decrease fetal weight 
and increase placental weight. ART procedures also cause aberrant expression of 
imprinted genes including H19, Igf2, Kcnq1ot1, Cdkn1c, Peg3 and Snrnp in the 
placenta during early placental development and is accompanied by expansion of the 
junctional zone towards the end of gestation (de Waal et al. 2014; de Waal et al. 
2015). These studies also indicate that the placenta is more susceptible to epigenetic 
aberrations than the fetus. However, the pathways and mechanisms through which 
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environmental insults during ART result in placental defects have not been identified.  
 
1.7 Fetal origins of adult disease 
 
The Barker hypothesis postulates that environmental insults in utero can affect the 
long-term health of the offspring (Barker 2004a; Barker 2004b). Several studies have 
shown an association between low birth weight and increased rate of cardiovascular 
disease and non-insulin dependent diabetes as adults (McMillen and Robinson 2005; 
Stocker and Cawthorne 2008; Briana and Malamitsi-Puchner 2009; Langley-Evans 
2009; Yajnik 2009). Metabolic and endocrine adaptations of the fetus in response to 
under nutrition or over nutrition are proposed to increase the risk of hypertension, type 
2 diabetes, coronary heart disease and hyperlipidemia (de Boo and Harding 2006). 
Several studies have highlighted the role of low birth weight caused by pre term birth 
or IUGR in short term and long term consequences on the health of the fetus. It has 
become increasingly important to develop efficient methods of diagnosing and 
preventing IUGR, recognizing at risk pregnancies and following up with treatment 
programs to control disorders arising from these pregnancies. 
 
1.8 MicroRNAs 
 
MicroRNAs (miRNAs) are a family of ~21 nucleotide long noncoding RNAs that 
control gene expression through post-transcriptional and transcriptional gene silencing 
mechanisms (Bartel 2004). miRNAs bind to complementary bases in the 3’UTRs of 
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mRNAs and cause degradation or translational inhibition of the transcript (Bartel 
2004). miRNAs regulate hundreds of targets, usually acting as switches or fine-tuning 
mechanisms to control gene expression in various physiological and pathological 
contexts. miRNAs can act as a ‘switch’ to downregulate its mRNA target(s) to a level 
below a functional threshold or/and as a ‘fine-tuning’ mechanism to adjust gene 
expression of several targets to reach expression levels required for specific cellular 
processes (Lewis et al. 2003; Bartel 2004).  
 
After miRNA genes are transcribed, they are processed into 70 nucleotide pre-
miRNAs by Drosha inside the nucleus and transported into the cytoplasm by Exportin 
5. Dicer processes these transcripts into miRNA-miRNA* duplexes and one strand is 
assembled into the RNA-induced silencing complex (RISC). The miRNA strand binds 
to its target by sequence complementarity and suppresses expression by mRNA 
cleavage (He and Hannon 2004). Based on their genomic location, miRNAs can be 
classified into intergenic and intronic. Intergenic miRNAs are located in un-annotated 
regions of the genome and transcribed from their unique promoters. Intronic miRNAs 
are believed to be transcribed along with and share promoters with the host gene (Lee 
et al. 2002; Kim and Kim 2007). Although there is some evidence that intronic 
miRNAs can be independently transcribed, a larger majority are processed from the 
host gene transcript. Co-expression and co-regulation of intronic miRNA with its host 
gene is proposed to have an antagonistic or synergistic effect. Intronic miRNAs can 
repress activity of genes activated by the host gene to have an antagonistic effect or 
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tune gene expression of transcripts to have a synergistic function with the host gene 
(Lutter et al. 2010).  
 
Functional characterization of several miRNAs in vivo, through knock-out 
mouse models, has shown that miRNAs unlike transcription factors are not master 
regulators of gene expression, but act as a rheostats that fine tune gene expression of 
regulatory networks to confer robustness to cells under environmental variability 
(Vidigal and Ventura 2015). With some exceptions (miR-205) (Wang et al. 2013), 
most individual miRNA knock-out mice have a modest or no apparent phenotype. 
 
1.9 Role of Egfl7/miR-126 in angiogenesis 
 
miR-126 is an intronic miRNA located in intron 7 of the gene Egfl7. Egfl7 is 
selectively expressed by actively proliferating endothelial cells during physiological 
and pathological angiogenesis (Soncin et al. 2003; Fitch et al. 2004). Egfl7 is also 
expressed in embryonic stem cells (ESCs), trophoblast stem cells (TSCs), primordial 
germ cells, neural stem cells and pre-implantation embryos beginning at the 8-cell 
stage (Fitch et al. 2004; Campagnolo et al. 2008; Lacko et al. 2014). The first Egfl7 
knock out models demonstrated vascular defects and partial embryonic lethality 
(Parker et al. 2004; Schmidt et al. 2007). However, along with deletion of Egfl7, miR-
126 expression was significantly reduced. A later study using an Eglf7-specific 
knockout with intact miR-126 expression does not display an overt phenotype during 
embryonic development (Kuhnert et al. 2008). However, recent studies in our lab have 
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demonstrated a critical role for Egfl7 for placental vascularization and embryonic 
growth (Lacko et al. 2017). Egfl7-/- placentas display gross defects in chorioallantoic 
branching morphogenesis, placental vascular patterning and >50% reduction in fetal 
blood space resulting in IUGR of the embryos. Eglf7-/- placental endothelial cells are 
deficient in migration, cord formation, and sprouting (Lacko et al. 2017). 
 
miR-126, present in intron 7 of Egfl7, has complete sequence conservation in 
vertebrates and has an expression pattern similar to EGFL7. The role of miR-126 in 
vascular development was studied in loss of function zebrafish and mouse models. 
miR-126 knock down in zebrafish resulted in loss of vascular integrity and 
hemorrhaging during embryonic development (Fish et al. 2008; Wang et al. 2008). 
miR-126-/- mice in which Egfl7 is intact display partial embryonic lethality and 
vascular defects in the embryo during development (Kuhnert et al. 2008; Wang et al. 
2008). miR-126-/- embryos displayed systemic edema, multifocal hemorrhages and 
demise, with highest percentage of embryos with vascular defects from E13.5 – E15.5. 
Electron microscopy showed extensive blood vessel rupture and lack of tight cell 
interactions in endothelial cells of miR-126-/- embryos. At E15.5 miR-126-/- embryos 
also displayed reduced numbers of BrdU+ PECAM+ proliferating endothelial cells. 
However, 60% of miR-126-/- survived to adulthood and displayed no major 
histological abnormalities. From this data, the authors conclude that miR-126 is 
essential for maintenance of vascular integrity during embryogenesis, but not essential 
for vascular homeostasis after birth (Wang et al. 2008). 
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The angiogenic response of endothelial cells (ECs) in miR-126-/- was tested 
using aortic ring and matrigel plug assays. Aortic rings isolated from 4-week old miR-
126−/− mice cultured on matrigel with endothelial growth medium containing FGF-2 
and VEGF and supplemented with 3% mouse serum displayed impaired endothelial 
outgrowth when compared to wild-type littermates (Wang et al. 2008). Since 
neoangiogenesis is critical for cardiac repair following myocardial infarction, the 
response of wild type and miR-126-/- mice following induced myocardial infarction 
was tested. 3 weeks following surgical ligation of the left coronary artery, only 50% of 
miR-126-/- survived, compared to survival rate of 70% of wild type littermates, with 
no surviving miR-126-/- 3 weeks after the procedure (Wang et al. 2008). Similar to the 
mouse model, impaired angiogenic response was observed in the miR-126 morpholino 
injected zebrafish (Fish et al. 2008). 
 
The molecular targets of miR-126 controlling angiogenic response were 
identified from gene expression profiles of kidney ECs from wild type and miR-126-/- 
mice (Wang et al. 2008). Functional assays using gain and loss of function of miR-126 
in primary endothelial cells and human umbilical vein endothelial cells (HUVECs) 
showed Spred-1 and PIK3R2 as direct targets of miR-126 (Wang et al. 2008). The 
results from the zebrafish and mouse models reveal an essential role for miR-126 in 
regulating developmental angiogenesis and vascular integrity in vivo (Fish et al. 2008; 
Wang et al. 2008). miR-126 regulates the angiogenic actions of VEGF and FGF by 
inhibiting Spred-1 and PIK3R2, inhibitors of the MAPK and AKT pathway 
respectively (Fish et al. 2008; Wang et al. 2008). miR-126 not only responds to 
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angiogenic growth factor stimuli, but also activates angiogenesis in response to the 
physiological stimulus of blood flow. 
 
miR-126 has also been shown to regulate endothelial-hematopoietic 
interactions and hematopoiesis. Inhibition of miR-126 in endothelial cells leads to 
increased SDF-1/CXCL12 expression, resulting in increased migration of Sca-1+/Lin- 
progenitor cells (van Solingen et al. 2011). miR-126 is also expressed in human 
hematopoietic cells (HSCs) and early progenitors. Loss of function and gain of 
function studies in HSCs have demonstrated a pivotal role for miR-126 in restraining 
cell cycle progression in vitro and in vivo by regulating multiple targets of 
PI3K/AKT/GSK3 pathway (Lechman et al. 2012) 
 
1.10 Summary and significance 
 
Normal placental development is crucial for the health of the mother and the fetus 
during gestation and for the long-term health of the fetus. Abnormal placentation 
contributes to the development and progression of a number of disease pathologies 
like preeclampsia, intra uterine growth restriction and gestational diabetes. 
 
A number of mouse models have been used to elucidate pathways and genes 
regulating development and intricate interactions of the vascular and trophoblast 
compartments of the placenta. A large number of studies have described the roles of 
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protein coding genes, however, the roles of miRNAs in placental development have 
not been well studied. 
 
miR-126 is a vascular specific intronic miRNA that plays a critical role in 
regulating angiogenesis during embryonic development. Due the functional role of 
miR-126 and its host gene Egfl7 in angiogenesis, we hypothesized that miR-126 plays 
an important role in placental development. To test this, I used a miR-126 loss-of-
function congenic mouse model. In this dissertation, in chapters 2 and 3, I describe a 
novel role for miR-126 in regulating the glycogen trophoblast proliferation in the 
placenta and demonstrate a functional role for miR-126 in regulating DNA 
methylation and genomic imprinting. In chapter 4, I will describe metabolic defects in 
miR-126+/- adult mice with potential roles for miR-126 in insulin secretion. 
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Chapter 2 – Novel role for miR-126 in regulating glycogen trophoblast 
proliferation in the murine placenta 
 
2.1 Rationale 
 
The placenta is critical for the development and survival of the mammalian 
embryo. It is responsible for nutrient, gas and waste exchange, as well as 
immunological and endocrine functions critical during pregnancy (Watson and Cross 
2005). The murine placenta develops from two major lineages, the trophectoderm and 
the extraembryonic mesoderm (Rossant and Cross 2001). Dysregulation of placental 
development can lead to abnormal placentation with adverse consequences for the 
mother and the fetus. Placental pathologies like preeclampsia and intra uterine growth 
restriction can lead to embryonic and maternal demise (Rossant and Cross 2001). 
 
miRNAs have been shown to play critical roles in human placental development. 
Several functional studies have revealed key roles for miRNAs in trophoblast 
proliferation, invasion, migration, hormone production and angiogenesis (Lee et al. 
2011; Ishibashi et al. 2012; Luo et al. 2012; Fu et al. 2013b; Li et al. 2013). Placental 
disorders like PE and IUGR are also associated with aberrant miRNA expression (Fu 
et al. 2013a) (Tsochandaridis et al. 2015). However, most of these functional studies 
rely on transformed trophoblast cell lines or cultures of primary trophoblast cells. To 
completely understand the roles played by miRNAs in placental development and 
disease, in vivo models are necessary. 
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Human and murine placentas are hemochorial, in which maternal blood comes in 
direct contact with the chorion. They are also thought to share molecular mechanisms 
controlling placental development (Watson and Cross 2005). Powerful genetic tools 
have enabled the use of murine models to study the roles of a single gene or 
combinations of gene networks in placental development. This has been particularly 
important in identifying targeted mutations associated with placental defects resulting 
in embryonic lethality. 
 
In this chapter I will describe a novel expression domain for miR-126 in the 
trophoblasts of the placenta and a functional role for miR-126 in regulating glycogen 
trophoblast proliferation. This data is part of a manuscript in revision (miR-126 
regulates glycogen trophoblast proliferation and DNA methylation in the murine 
placenta. Abhijeet Sharma, Lauretta A. Lacko and Heidi Stuhlmann. In 
revision, Development). 
 
2.2 Abstract 
 
A functional placenta develops through a delicate interplay of its vascular and 
trophoblast compartments. Placental insufficiencies can lead to adverse outcomes for 
the mother and the fetus. We have identified a novel expression domain for the 
endothelial-specific microRNA miR-126 in trophoblasts of murine and human 
placentas. Here, we determine the role of miR-126 in placental development using a 
mouse model with a targeted deletion of miR-126. miR-126-/- mice in a congenic 
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C57BL/6J background die in utero. Loss-of miR-126 leads to significant hyperplasia 
in the junctional zone at E15.5 at the expense of the labyrinth, resulting in reduced 
placental volume for nutrient exchange and intra-uterine growth restriction of the 
embryos. Junctional zone hyperplasia results from increased numbers of proliferating 
glycogen trophoblast progenitors at E13.5 that give rise to an expanded glycogen 
trophoblast population at E15.5. 
 
2.3 Introduction 
 
A recent study revealed a novel expression domain for the endothelial specific 
gene Egfl7 in the trophectoderm and trophoblasts of the placenta(Lacko et al. 2014). 
miR-126 is a microRNA (miRNA) that is embedded in intron 7 of Egfl7 and shares 
upstream regulatory elements with Egfl7 (Kuhnert et al. 2008; Wang et al. 2008). 
miR-126 knock-out mice display vascular leakage, hemorrhaging and partial 
embryonic lethality (Kuhnert et al. 2008; Wang et al. 2008). The vascular defects can 
be attributed to diminished sprouting and adhesion of endothelial cells resulting from 
reduced PI3K and MAPK signaling. Studies in zebrafish and mice revealed that, miR-
126 modulates developmental angiogenesis by post transcriptionally regulating gene 
expression of Spred1 and Pik3r2, inhibitors of Akt and Erk signaling (Fish et al. 2008; 
Wang et al. 2008). However, the expression of miR-126 in the placenta and function 
of miR-126 during placental development has not been investigated. 
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Here, the role of miR-126 in placental development was examined using the 
miR-126-/- mouse model developed by Dr. Eric Olson’s laboratory (Wang et al. 2008). 
In a congenic background, we show that the endothelial specific miRNA, miR-126 
displays a novel expression domain in the trophoblasts of the murine placenta. miR-
126-/- placentas have increased numbers of proliferating glycogen trophoblast 
progenitor cells during mid-gestation, leading to an expanded junctional zone and 
reduced size of the fetal labyrinth of the placenta, all of which results in late 
gestational intra uterine growth restriction of the embryos. 
 
2.4 Results and Discussion 
 
2.4.1 Embryonic lethality of miR-126-/- embryos and late gestational intra-uterine 
growth restriction in a C57BL/6J background 
 
Previous studies showed that miR-126-/- mice in a mixed genetic background 
display angiogenic defects, including leaky vessels, hemorrhaging, and partial 
embryonic lethality with incomplete penetrance (Kuhnert et al. 2008; Wang et al. 
2008) To explore the function of miR-126 in a congenic background, miR-126+/- mice 
were backcrossed for ten generations into a C57BL/6J background. Intercrosses of 
congenic miR-126+/- mice failed to produce any surviving miR-126-/- pups at postnatal 
day10 (P10) (Fig 2.1A). To determine the time of demise of miR-126-/- embryos, 
litters from miR-126+/- intercrosses were genotyped at different gestational stages. 
Only 6% (3 out of 52) of embryos at embryonic day 18.5 (E18.5) and 12% (14 out of 
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112) at E15.5 were miR-126-/-. However, at E12.5, miR-126-/- embryos were observed 
at the expected 25% ratio (24 out of 98) (Fig. 2.1A). Vascular defects, including 
hemorrhaging at E12.5 and systemic edema at E15.5 (Kuhnert et al. 2008; Wang et al. 
2008) were observed with complete penetrance in miR-126-/- embryos in a congenic 
C57BL/6J background (Fig 2.1B). A fraction of miR-126+/- embryos (~50%) 
displayed similar vascular defects. The sizes and weights of embryos and placentas at 
E12.5 and E15.5 were measured. miR-126-/- embryos at E15.5 had significantly lower 
crown-to-rump lengths and reduced wet weights when compared to miR-126+/+ 
littermates (Fig 2.1D), consistent with late gestational intra-uterine growth restriction 
(IUGR). No significant differences in weights and crown to rump lengths between 
miR-126-/- and miR-126+/+ embryos were detected at E12.5 (Fig 2.1C). Furthermore, 
no significant differences in placental lengths and weights were detected at E12.5 or 
E15.5 (Fig 2.1C,D). 
 
2.4.2 miR-126 is expressed by trophoblast and endothelial cells of the placenta. 
 
During embryonic development, Egfl7 and miR-126 expression is restricted to the 
endothelium (Fitch et al. 2004; Parker et al. 2004; Wang et al. 2008; Bambino et al. 
2014). Interestingly, during placental development Egfl7 is expressed in the 
trophectoderm, in trophoblast stem cells (TSCs) and in junctional zone trophoblasts, in 
addition to maternal and fetal endothelial cells (Lacko et al. 2014). 
 
Expression levels of miR-126-3p were comparable in E12.5 placentas and  
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Figure 2.1 miR-126-/- mice in a congenic C57BL/6J background die in utero and 
display late gestational IUGR. Genotypes of offspring from miR-126+/- intercrosses. 
The observed and expected numbers of mice and embryos for each genotype at each 
developmental stage are shown (A). Representative images of miR-126+/+ and miR-
126-/- littermate embryos and placentas at E12.5 and E15.5 (B). Lengths (mm) and wet 
weights (mg) of embryos and placentas from miR-126+/+ (n=7) and miR-126-/- (n=8) 
conceptuses at E12.5. Error bars indicate SEM (C). Lengths (mm) and wet weights 
(mg) of embryos and placentas from miR-126+/+ (n=25) and miR-126-/- (n=6) 
conceptuses at E15.5. Error bars indicate SEM. (** p≤0.01) (D). 
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embryos and undetectable in miR-126-/- embryos and placentas, as determined by 
quantitative RT-PCR (Fig. 2.2A). Expression levels of miR-126 were comparable in 
TSCs and embryonic stem cells (ESCs) (Figure 2.2B). To visualize localization of 
miR-126 in the murine placenta, in situ hybridization was performed using a miR-126 
specific LNA probe. miR-126-/- littermate placentas were used as controls for probe 
specificity. At E12.5, miR-126 is localized in the trophoblast giant cells (Fig. 2.2C, 
top panel, green arrow) and spongiotrophoblasts (Fig. 2.2C, top panel, red arrow) of 
the junctional zone. miR-126 expression was also detected in endothelial cells (Fig. 
2.2C, bottom panel, green arrow) and syncytiotrophoblasts of the fetal labyrinth (Fig. 
2.2C, bottom panel, red arrow). No positive signal was detected in miR126-/- placentas 
demonstrating specificity of the probe (Fig. 2.2C). miR-126 expression could also be 
seen in syncytiotrophoblasts (Fig. 2.2D, top panel, red arrow), cytotrophoblasts (Fig. 
2.2D, bottom panel, blue arrow) and fetal endothelial cells (Fig. 2.2D, bottom panel, 
black arrow) in sections of term human placentas. No positive signal was detected in 
tissue hybridized with a scrambled LNA probe (Fig. 2.2D). Together, these findings 
demonstrate a novel expression domain for miR-126 in trophoblast stem cells and 
several trophoblast cell subtypes in murine and human placentas, in addition to its 
expression in fetal endothelial cells. 
 
2.4.3 Hyperplasia of the junctional zone in miR-126-/- placentas at E15.5 
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Figure 2.2 Trophoblasts and endothelial cells of murine and term human 
placentas express miR-126. Quantification of miR-126-3p expression in miR-126+/+ 
(n=3) and miR-126-/- (n=3) embryos and placentas at E12.5 by quantitative RT PCR. 
Error bars indicate SEM. Expression levels are normalized to levels in miR-126+/+ 
embryos (A). Quantification of miR-126-3p levels in trophoblast stem cells (TSC), 
embryonic stem cells (ESC) and mouse embryonic fibroblasts (MEF) by quantitative 
RT PCR (n=3; technical replicates). Error bars indicate SEM (B). Representative 
images of sections from E12.5 miR-126+/+ and miR-126-/- placentas hybridized with a 
DIG-labeled miR-126 LNA probe. Top panels: miR-126 specific expression is 
detected in the junctional zone in trophoblast giant cells (green arrow) and 
spongiotrophoblasts (red arrow) of miR-126+/+, but not miR-126-/- placentas. Bottom 
panels: miR-126 specific expression is detected in the fetal labyrinth in endothelial 
cells (green arrow) and syncytial trophoblasts (red arrow) of miR-126+/+, but not miR-
126-/- placentas. Bar = 100 µm (C). Representative images of human term placenta 
sections hybridized with a DIG- labeled miR-126, or a DIG-labeled scrambled LNA 
probe. Top Panels: miR-126 specific expression is detected in the syncytiotrophoblasts 
(red arrow) in sections stained with DIG-labeled miR-126 LNA probe, but not in 
sections hybridized with DIG-labeled scrambled LNA probe. Bottom panels: miR-126 
specific expression is detected in fetal endothelial cells (black arrow) and 
cytotrophoblasts (blue arrow) in sections hybridized with DIG-labeled miR-126 LNA 
probe, but not in sections stained with DIG-labeled scrambled LNA probe. Bar = 100 
µm (D). 
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 Placental sections from miR-126-/- (n=3) and miR-126+/+ (n=4) littermates were 
immunostained with Tpbpa antibodies to mark junctional zone (JZ) trophoblasts, and 
CD31 antibodies to mark endothelial cells of the fetal labyrinth (Lab) and the maternal 
decidua. Visual inspection showed an enlarged JZ in miR-126-/- placentas (Fig. 2.3A). 
Quantitative analysis showed a significant increase of the junctional zone area 
concomitant with a significant decrease in fetal labyrinth area in miR-126-/- placentas 
(Fig. 2.3B). This is further illustrated by a significantly reduced Lab/JZ ratio in miR-
126-/- placentas (Fig. 2.3C). The increase in junctional zone area is a result of 
significantly increased numbers of Tpbpa+ trophoblast cells in miR-126-/- placentas 
compared to miR-126+/+ littermates (Fig. 2.3D). In contrast, there were no significant 
differences in the size of the decidua or of the total placental area between miR-126+/+ 
and miR-126-/- placentas (Fig. 2.3B). Together, this data is consistent with a reduced 
labyrinth area as a potential cause for the observed IUGR and reduced viability of 
miR-126-/- embryos at E15.5 (Fig. 2.1A and 2.1D). Consistent with the absence of 
IUGR in miR-126-/- conceptuses at E12.5, placental labyrinth and junctional zone 
areas in miR-126-/- and miR-126+/+ conceptuses were similar in size at E12.5 (Fig 2.4). 
 
Unexpectedly, in contrast to the vascular defects observed in miR-126-/- 
embryos, the vasculature in the fetal labyrinth of miR-126-/- placentas appeared normal 
(Fig. 2.5A). No significant differences in the average vessel area (Fig. 2.5B), the 
numbers of Erg+ endothelial cells (Fig. 2.5D) or Erg+EdU+ proliferating endothelial  
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Figure 2.3 miR-126-/- placentas at E15.5 display expanded junctional zones and 
reduced fetal labyrinths. Representative images of E15.5 miR126+/+ and miR-126-/- 
placental sections, immunostained with antibodies against CD31 (green) to mark the 
endothelium of the labyrinth (Lab) and maternal arteries, and Tpbpa (red) to mark 
trophoblasts of the junctional zone (JZ). Dotted white lines indicate the junctional 
zone/labyrinth and junctional zone/decidua boundaries (A). Quantification of the areas 
of the fetal labyrinth (CD31, green), junctional zone (Tpbpa, red) and the decidua 
(gray) as a fraction of the total area (fetal labyrinth+ junctional zone+ decidua) of 
miR-126+/+ (n=4) and miR-126-/- (n=3) placentas. Error bars indicate SEM. (* p≤0.05) 
(B). Ratio of labyrinth (Lab) to junctional zone (JZ) area in miR-126+/+ and miR-126-/- 
placentas at E15.5. Measurements obtained from placentas shown in panel B were 
used.  For miR-126+/+ placentas the ratio is set artificially at 1. Error bars indicate 
SEM (* p≤0.05) (C). Quantification of Tpbpa+ cells in miR-126+/+ (n=4) and miR-126-
/- (n=3) placentas at E15.5. Error bars indicate SEM (* p≤0.05) (D). 
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cells  (Fig. 2.5E) were observed between miR-126+/+ and miR-126-/- placentas at 
E12.5. 
 
2.4.4 Increased numbers of glycogen trophoblasts in miR-126-/- placentas at E15.5 
 
The observed expansion of the junctional zone trophoblasts in miR-126-/- placentas 
at E15.5 suggested an increase in the numbers of spongiotrophoblasts, glycogen 
trophoblasts, or both as the underlying cause. To identify the affected cell type(s), we 
performed co-immunostaining of E15.5 miR-126+/+ and miR-126-/- placentas with  
antibodies for Tpbpa and p57Kip2 (Fig. 2.6A). Spongiotrophoblasts and glycogen 
trophoblast cells (GlyTs) of the junctional zone express the trophoblast specific gene 
Tpbpa (Adamson et al. 2002). Placental GlyTs but not spongiotrophoblasts express the 
imprinted gene p57Kip2 (Cdkn1c) (Georgiades et al. 2002; Coan et al. 2006). Large 
clusters of GCs (Tpbpalowp57Kip2+) were detected in the junctional zones of miR-126-/- 
and miR-126+/+ placentas (Fig. 2.6A, arrows). Quantification of GlyTs and 
spongiotrophoblasts showed that miR-126-/- placentas contain significantly increased 
numbers of Tpbpalowp57Kip2+ GCs in the junctional zone (Fig. 2.6B). In contrast, no 
significant difference in the numbers of Tpbpahighp57Kip2- spongiotrophoblasts was 
detected (Fig. 2.6C). We next analyzed glycogen content in GlyT clusters by 
performing periodic acid-schiff (PAS) staining on sections from paraffin-embedded 
placental tissue at E15.5. Visual inspection revealed larger PAS positive GlyT clusters 
in miR-126-/- placentas compared to miR-126+/+ placentas (Fig. 2.6D). We also 
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quantified the glycogen content in the placental tissue by colorimetry (Kemp and Van 
Heijningen 1954). miR-126-/- placental tissue contained significantly increased 
amounts of glycogen when compared to miR-126+/+ littermates (Fig. 2.6E). Together, 
these results indicate that miR-126-/- placentas contain increased numbers of 
terminally differentiated glycogen trophoblasts that results in a significantly increased 
junctional zone area at E15.5. 
 
2.4.5 Increased numbers of proliferating glycogen cell progenitors in miR-126-/- 
placentas at E13.5 
 
To determine if the increased number of GlyTs in the junctional zone was a result of 
increased cell proliferation, we performed an EdU proliferation assay. EdU was 
intravenously injected into E15.5 pregnant females from miR-126+/- intercrosses, 
followed by co-immunostaining of placental sections with antibodies for p57Kip2 and 
Tpbpa. Few proliferating cells were detected in the junctional zone at E15.5 (Fig. 
2.7A). This is consistent with a previous study reporting a 4-fold increase in 
spongiotrophoblasts and a 250-fold increase in glycogen trophoblasts between E12.5 
and E16.5, with proliferation ceasing by E16.5 (Coan et al. 2006). To quantify 
proliferating progenitor cells at the time of trophoblast cell proliferation in the 
junctional zone, EdU injections and immunostaining of placentas were performed at 
E13.5 (Fig. 2.8A). 	
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Figure 2.4 miR-126-/- placentas at E12.5 do not display junctional zone 
hypertrophy. Representative images of E12.5 miR126+/+ and miR-126-/- placentas 
immunostained with antibodies against CD31 to mark the endothelium of the labyrinth 
(Lab) and maternal arteries and Tpbpa to mark trophoblasts of the junctional zone 
(JZ). Bar = 100mm. (A). Quantification of the areas of the fetal labyrinth (CD31, 
green), junctional zone (Tpbpa, red) and the decidua (gray) as a fraction of the total 
area (fetal labyrinth+ junctional zone + decidua) of miR-126+/+ (n=4) and miR-126-/- 
(n=4) placentas (3 sec1ons 100µm apart at the placental midline. Error bars indicate 
SEM (B). Ratio of labyrinth to junctional zone area in miR-126+/+ and miR-126-/- 
placentas at E12.5. Measurements obtained from placentas shown in panel B were 
used. For miR-126+/+ placentas the ratio is set artificially at 1. Error bars indicate 
SEM. (C). 
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Figure 2.5 miR-126-/- placentas at E12.5 do not display overt vascular phenotypes. 
Representative images of the fetal labyrinth from E12.5 miR126+/+ and miR-126-/- 
placentas immunostained with antibodies against ENDOMUCIN to mark the fetal 
endothelium of the labyrinth and CYTOKERATIN to mark trophoblasts (A). 
Quantification of the average area of fetal vessels in the fetal labyrinth of miR-126+/+ 
(n=4) and miR-126-/- (n=4) placentas. Error bars indicate SEM (B). Representative 
images of E12.5 miR126+/+ and miR-126-/- placentas immunostained with an ERG 
antibody to mark the fetal endothelium of the labyrinth and EdU to mark proliferating 
cells (ClickiT chemistry) (C). Quantification of Erg+ endothelial cells in the fetal 
labyrinth zone of miR-126+/+ (n=4) and miR-126-/- (n=4) placentas. Error bars indicate 
SEM (D). Quantification of EdU+ Erg+ proliferating endothelial cells in the fetal 
labyrinth zone of miR-126+/+ (n=4) and miR-126-/- (n=4) placentas. Error bars indicate 
SEM (E). 
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Figure 2.6 Increased numbers of glycogen trophoblasts in miR-126-/- placentas at 
E15.5. Representative immunofluorescence images of section from miR-126+/+ and 
miR-126-/- E15.5 placentas co-immunostained with a p57Kip2 antibody to mark 
glycogen trophoblast cells and a Tpbpa antibody to mark junctional zone trophoblasts. 
Arrows indicate clusters of Tpbpalowp57+ glycogen trophoblast cells in the junctional 
zone. Bar = 1 mm (A). Quantification of Tpbpalowp57+ glycogen trophoblast cells in 
the junctional zone of miR-126+/+ (n=4) and miR-126-/- (n=3) placentas. Data are 
shown as % of total number of cells in each image. Error bars indicate SEM (* 
p≤0.05) (B). Quantification of Tpbpahighp57- spongiotrophoblasts in the junctional 
zone (C). PAS stain of representative paraffin sections from miR126+/+ and miR-126-/- 
E15.5 placentas. Arrows indicate glycogen trophoblast clusters in the junctional zone 
(D). Quantification of glycogen content in miR-126+/+ (n=6) and miR-126-/- (n=3) 
placentas.  Error bars indicate SEM. (** p≤0.01) (E). 
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Quantification of glycogen progenitors and proliferating glycogen progenitors in the 
junctional zone revealed that miR-126-/- placentas (n=4) contain a significantly higher 
fraction of Tpbpa+p57Kip2+ glycogen trophoblast progenitors (Fig. 2.8B) and, most 
importantly, a significantly higher proportion of EdU+Tpbpa+p57Kip2+ proliferating 
glycogen progenitors (Fig. 2.8C) when compared to miR-126+/+ placentas (n=4). No 
significant differences in the fraction of Tpbpa+ (spongiotrophoblasts) (Fig. 2.8D) or 
Tpbpa+ EdU+ trophoblasts (proliferating spongiotrophoblasts) were detected in the 
junctional zone between miR-126+/+ and miR-126-/- placentas (Fig. 2.8E). These 
results indicate that loss-of miR-126 leads to increased numbers of proliferating 
glycogen trophoblast progenitors at E13.5, resulting in increased numbers of 
differentiated GlyTs and an expanded junctional zone in E15.5 placentas, concomitant 
with a reduced fetal labyrinth area. 
 
Discussion 
 
The results presented in this study reveal a novel role for miR-126 in regulating GlyT 
proliferation placental development. Loss-of-miR-126 resulted in a mutant phenotype 
that was restricted to the trophoblasts of the placenta. miR-126-/- placentas contain 
increased numbers of proliferating GlyT progenitors resulting in hyperplasia of the 
junctional zone at the expense of the fetal labyrinth, concomitant with late gestational 
IUGR of the embryos. This phenotype was unexpected, since miR-126-/- embryos and 
adult mice display vascular phenotypes and defects in angiogenesis (Kuhnert et al. 
2008; Wang et al. 2008) and expression of miR-126 was thought to be endothelial  
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Figure 2.7 Reduced numbers of proliferating cells in the junctional zone of 
placentas at E15.5. Representative images of sections of miR-126+/+ and miR-126-/- 
placentas at E15.5, immunostained with p57Kip2 antibody, Tpbpa antibody and EdU 
(ClickiT chemistry) (A) 
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cell-specific. In contrast, vascular phenotypes were absent in the fetal labyrinth of 
miR-126-/- placentas (Fig. 2.5). This result may reflect the fact that the endothelial cell 
lineage in the fetal labyrinth is derived from the extraembryonic mesoderm of the 
allantois whereas all embryonic and adult endothelial cells are derived from the 
mesoderm of the embryo proper. In support, the transcriptome of the placental 
endothelium is unique when compared to that of other vascular beds (Nolan et al. 
2013). Mice with loss-of-function of the host gene Egfl7 display vascular patterning 
defects in the fetal labyrinth but lack an overt phenotype in the embryonic or adult 
vasculature (Lacko et al. 2017). The integration of microRNAs into introns of protein 
coding genes provides a common mechanism to coordinate expression and the 
regulatory functions of microRNAs with the gene networks regulated by the host gene 
(Wang et al. 2008; Liu and Olson 2010). Co-expression of miR-126 and Egfl7 in the 
endothelium in embryos and adult mice is controlled by a 5’ 5.4-kb regulatory region 
that contains conserved consensus sequences for binding of Ets transcription factors 
(Wang et al. 2008; Bambino et al. 2014).  miR-126 is generated from a retained intron 
in a subset of Egfl7 pre-mRNAs (Wang et al. 2008). In the placenta, miR-126 and 
Egfl7 are co-expressed in the trophoblast lineage, in addition to its expression in the 
fetal and maternal endothelium.  Specifically, we detected miR-126 transcripts, Egfl7 
transcripts and protein in junctional zone trophoblasts of the murine placenta and in 
cytotrophoblasts and syncytiotrophoblasts of term human placenta, and in mouse 
TSCs (Lacko et al. 2014). 
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Figure 2.8: Increased numbers of proliferating glycogen trophoblast progenitors 
in E13.5 miR-126-/- placentas at E13.5. Representative images of sections of miR-
126+/+ and miR-126-/- placentas at E13.5, immunostained with p57Kip2 antibody, Tpbpa 
antibody and EdU (ClickiT chemistry). Dotted white line indicates the boundary 
between the junctional zone and labyrinth. Bar = 100mm (A). Quantification of 
Tpbpa+p57+ glycogen trophoblasts in the junctional zone of miR-126+/+ (n=4) and 
miR-126-/- (n=4) placentas. Error bars indicate SEM. (* p≤0.05) (B). Quantification of 
EdU+Tpbpa+p57+ proliferating glycogen trophoblast progenitor cells in the junctional 
zone of miR-126+/+ (n=4) and miR-126-/- (n=4) placentas. Error bars indicate SEM. 
(** p≤0.01) (C). Quantification of Tpbpa+ trophoblasts in the junctional zone (D). 
Quantification of EdU+Tpbpa+ proliferating cells in the junctional zone (E). 
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Our study is the first to implicate a role for a microRNA in GlyT proliferation and 
regulation of imprinted gene expression specifically in the placenta. The function of 
the GlyT lineage in the placenta is largely unknown; however, their migration into the 
decidua during late gestation and subsequent release of glucose into the maternal 
bloodstream supports the hypothesis that they are important for supplementing 
maternal nutrient resources and regulating embryonic growth during late gestation 
(Coan et al. 2006). 
 
2.5 Materials and methods 
 
Mice and genotyping 
All animal protocols were approved and are in accordance with the Institutional 
Animal Care and Use Committee (IACUC) at Weill Cornell Medical College of 
Cornell University. miR-126+/- mice (Wang et al. 2008) in a mixed genetic 
background were obtained from Dr. Eric Olsen (UT Southwestern Medical Center) 
and backcrossed for 10 generations into a congenic C57Bl6/J background. Genotyping 
was done by genomic PCR on DNA from yolk sac or tail biopsies, using the following 
primers:  
126wild-forward:  5’- GGGCCACTTTACCCTGAAGAG -3’; 
126wild-reverse: 5’-GCTGACCGCGCATTATTACTC-3’; 
126floxed-reverse: 5’ – GACGGTATCGATAAAGCTAGC-3’.  
For timed pregnancies, the day of a vaginal plug was designated as embryonic day 0.5. 
All experimental embryos and placentas were isolated from litters of miR-126+/- x 
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miR-126+/- crosses. Embryonic sizes were calculated by crown to rump length 
measurements and placental sizes were calculated by measurements along the 
diameter of the placenta. 
 
Quantitative real-time PCR 
Embryos and placentas (E12.5) were isolated in cold PBS and flash frozen in liquid 
nitrogen. RNA was isolated using Trizol (Invitrogen). For analysis of miR-126 
expression, 10ng of RNA was reverse transcribed using TaqMan MicroRNA Reverse 
Transcription Kit (Life Technologies #4366596) with RT primers specific for 
miR126-3p (002228) and control snoRNA234 (0001234). Real Time PCR was 
performed using TaqMan Universal PCR Master Mix (Life Technologies #4324018) 
and TaqMan probes for miR126-3p and control snoRNA234. 
 
In situ hybridization 
In situ hybridization was performed as previously described (Nielsen 2012). Briefly, 
OCT embedded mouse and human placenta sections were post-fixed with 4% PFA for 
10mins and washed with PBS. Slides were treated with an acetylation solution (500µl 
6N HCl, 670µl triethanolamine, 300µl acetic anhydride in 48.5ml DEPC-treated 
water) for 5min at RT. Sections were pre-hybridized in hybridization buffer (50% 
formamide, 5x SSC, 500µg/µl yeast tRNA, 5mM EDTA, 1X Denhardt’ solution) for 
4hr at 550C, and incubated with a DIG-labeled LNA miR-126 LNA probe (Exiqon) for 
4hr at 550C. Slides were washed twice with 0.1x SSC at 600C and 4 times with 2x 
SSC at RT, blocked for 1hr using a blocking buffer (10% blocking reagent, 20% heat 
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inactivated goat serum in MABT) and incubated overnight at 40C with alkaline 
phosphatase-conjugated anti-DIG antibody (1:1600, Roche). Sections were washed 
with MABT and NTMT (100 mM NaCl, 100 mM Tris–HCl pH9.5, 50 mM MgCl2, 
1% Tween20, 20 µM Levamisole, in H2O). Signal was detected using NBT-BCIP 
(Roche) at RT. Sections were post-fixed in 4% paraformaldehyde and imaged using an 
Axioplan 2 imaging microscope (Carl Zeiss) with 20X and 40X objectives. 
 
Histology and Immunohistochemistry 
Placentas were isolated in ice-cold PBS, fixed in 4% paraformaldehyde overnight, and 
embedded in an OCT: 30% sucrose mixture. Cryosections were permeabilized in 0.5% 
Triton-X/0.1% Saponin/PBS (TSP) and blocked with 1% donkey serum in 0.1% 
TSP/PBS (PBS–TSP). Sections were incubated overnight at 4°C with primary 
antibodies - CD31 (BD Biosciences, 553370, 5µg/ml); Cytokeratin (DAKO Z0622, 
10µg/ml); Tpbpa (Abcam, ab104401, 10µg/µl); p57 (Santa Cruz, sc-1039, 20µg/µl); 
Erg (Abcam, ab110639, 0.17µg/ml) -, followed by incubation with secondary 
antibodies (Alexa488-donkey-α-rat, Alexa488-donkey-α-rabbit, Alexa488-donkey-α-
goat and Alexa594-donkey-α-rabbit, Jackson Immunoresearch, 1.5 µg/ml), and 
mounted with Prolong Gold + DAPI. Images were acquired using an Axioplan 2 
imaging microscope with 20X and 40X objectives. 
 
Measurement of labyrinth and junctional zone areas  
Labyrinth and junctional zone areas were quantified from 6 images each of CD31 and 
Tpbpa immunostained cryosections from miR-126+/+ (n=4) and miR-126-/- (n=3) 
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placentas derived from at least two litters of miR-126+/- x miR-126+/- crosses. The area 
stained positive for CD31 was quantified as the fetal labyrinth area, and the area 
stained positive for Tpbpa was quantified as the junctional zone area. Labyrinth and 
junctional zone regions were traced using ImageJ software and the percentage area 
was quantified. 
 
PAS staining 
Placentas were isolated, fixed in 4% paraformaldehyde, dehydrated through a series of 
alcohols, and embedded in paraffin. Sections were deparaffinized and hydrated 
through a series of alcohols to distilled water, stained with 1% Periodic acid for 5 
minutes, and rinsed in distilled water. Sections were then stained with Schiff’s reagent 
(Sigma) at room temperature for 30 minutes, washed in running tap water for 5 
minutes, counterstained with Hematoxylin, and mounted with Permount (Fisher 
Scientific). Images were acquired using an Axioplan 2 imaging microscope with a 
20X objective. 
 
EdU Labeling 
Proliferating cells were labeled using the Click-iT EdU Imaging Kit (Life 
Technologies, C10339), as previously described (Lacko et al. 2017). Briefly, pregnant 
female miR-126+/- mice were subjected to intraperitoneal injection of EdU at 50 µg per 
gram of body weight at day 13.5 and day 15.5 of gestation. After 60 minutes, mice 
were euthanized and placentas were isolated and fixed in 4% paraformaldehyde 
overnight. Tissue was embedded in an OCT: 30% sucrose mixture and sectioned for 
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further processing. EdU detection was carried out according to the manufacturer’s 
protocol. Antibody staining was then performed as described above. Approximately 
every 10th section was used for quantification of labeling, for a total of four sections 
per placenta (n=4 per genotype), and analyzed using ImageJ, Metamorph (Molecular 
Devices) and Prism (GraphPad) software. 
 
Cell counts 
Glycogen trophoblast and proliferating cells were quantified from 10-15 high 
magnification images of miR-126+/+ (n=4) and miR-126-/- (n=4) immunostained 
placentas from at least two litters of miR-126+/- x miR-126+/- crosses. p57Kip2+Tpbpalow 
cells in the junctional zone of E13.5 and E15.5 placentas and EdU+ p57Kip2+Tpbpalow 
cells in the junctional zone of E13.5 were quantified using MetaMorph imaging 
software. Trophoblast giant cells were excluded based on the size of their nuclei. 
 
Quantification of total glycogen from placental tissue 
Total glycogen content in placentas was measured using previously described methods 
(Kemp and Van Heijningen 1954). Briefly, placentas were weighed, and boiled for 20 
min in a 30% KOH solution saturated with Na2SO4. After cooling on ice, glycogen 
was precipitated by adding 1.2 volumes of 95% ethanol. Samples were spun at 1000xg 
for 30min at 4oC, and the glycogen pellet was dissolved in ddH20. A phenol-sulfuric 
acid colorimetric method was used to determine glycogen content (Kemp and Van 
Heijningen 1954). 
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Chapter 3- Gene expression and signaling in miR-126-/- placentas 
 
 
3.1 Rationale 
 
 
A number of genetic and epigenetic determinants control trophoblast 
differentiation and placental development (Maltepe et al. 2010; Lefebvre 2012). 
Genomic imprinting is an epigenetic modification that regulates gene expression from 
a single allele based on parental origin (Plasschaert and Bartolomei 2014). The 
importance of maintaining genomic imprints for placental development is highlighted 
in murine models where imprinted gene deletions and uniparental duplications result 
in placental abnormalities and embryonic growth defects (Lopez et al. 1996; 
Georgiades et al. 2001; Esquiliano et al. 2009; Tunster et al. 2010; Oh-McGinnis et al. 
2011). Human infants with naturally occurring imprinting disorders like Beckwith–
Wiedemann and Silver-Russell syndromes have abnormal placentas (Maher and Reik 
2000; Gicquel et al. 2005; Schonherr et al. 2007). Genomic imprinting also affects 
nutrient availability and tissue development in utero (Tunster et al. 2013; Green et al. 
2015). Interestingly, several known regulators of junctional zone trophoblast 
development are imprinted genes that are located in the Igf2 and Kcnq1ot1 clusters on 
the distal end of chromosome 7 (Fig. 3.1) (Ferguson-Smith et al. 2001; Lefebvre 
2012). Genomic imprinting is regulated by the maintenance DNA methyl transferase, 
Dnmt1. Dnmt1 catalyzes methylation of hemi-methylated CpG nucleotides at 
differentially methylated regions (DMRs) of imprint control centers (Messerschmidt et 
al. 2014). Dnmt1o (oocyte specific) deficiency results in partial loss of DNA 
methylation and placental defects, including an expanded spongiotrophoblast volume, 
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aberrant glycogen trophoblast migration and reduced surface area for maternal fetal 
gas exchange (Himes et al. 2013). 
 
In the previous chapter, I have described defects in glycogen trophoblast 
progenitor proliferation in miR-126-/- placentas that result in junctional zone 
expansion, reduced fetal labyrinth and IUGR of the embryos. In this chapter, I will 
describe a role for miR-126 in regulating imprinted gene expression by modulating 
DNA methylation as a possible mechanism for aberrant glycogen trophoblast 
proliferation. The results described in this chapter are from studies designed and 
performed by myself. They are part of a manuscript in revision (miR-126 regulates 
glycogen trophoblast proliferation and DNA methylation in the murine placenta 
Abhijeet Sharma, Lauretta A. Lacko and Heidi Stuhlmann. In revision. Development). 
 
 
3.2 Abstract 
 
 
 miR-126-/- placentas display an expanded junctional zone at E15.5 resulting 
from increased numbers of proliferating glycogen trophoblast progenitors. Several 
imprinted genes have been implicated in regulating glycogen trophoblast 
development. We show that miR-126-/- placentas display aberrant expression of 
imprinted genes with important roles in glycogen trophoblasts and junctional zone 
development, including Igf2, H19, Cdkn1c, Ascl2 and Phlda2. Abnormal imprinted 
gene expression is restricted to the placenta and is accompanied by methylation 
defects at several CpGs at ICRs of Kcnq1ot1 and H19. miR-126-/- placentas also 
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display dysregulated expression of the imprinting regulator, Dnmt1, and changes in 
global methylation. Our findings uncover a novel role for miR-126 in regulating 
expression of imprinted genes and DNA methylation in the placenta to regulate the 
extra-embryonic energy stores in the placenta. 
 
3.3 Introduction 
 
 
 A number of imprinted genes with roles in development of the junctional zone 
and glycogen trophoblasts (GlyTs) are located in two distinct clusters on mouse 
chromosome 7. Allele specific expression of imprinted genes in these clusters is 
regulated by differentially methylated regions (DMRs) function as imprint control 
centers (ICRs). A number of these imprinted genes are also implicated in the etiology 
of Beckwith–Wiedemann syndrome (BWS), Silver–Russell syndrome (SRS) and 
IUGR in humans, characterized by growth abnormalities of the embryo and placenta 
(Maher and Reik 2000; Constancia et al. 2002; Gicquel et al. 2005; Schonherr et al. 
2007; Esquiliano et al. 2009). 
 
Two independent ICRs, IC1 and IC2 on chromosome 7 control imprinting at the 
H19/Igf2 and Kcnq1 clusters through different mechanisms. The IC1 DMR controls 
paternal expression of Igf2 and maternal expression of H19 in embryos and placentas 
(Fig. 3.1). Allele specific expression is maintained by binding of the CTCF insulator 
protein to 4 target sites at the ICR. On the paternal allele, methylation at the ICR 
prevents CTCF binding, abrogates H19 expression and activates Igf2 expression 
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through the distal enhancer. On the maternal allele, insulator CTCF proteins bind the 
ICR, inhibiting access of the distal enhancer to Igf2 and activating H19 expression 
(Bell and Felsenfeld 2000; Hark et al. 2000). 
 
At the IC2 cluster, the lncRNA Kcnq1ot1 is expressed only from the paternal 
allele and methylation of its promoter on the maternal allele acts as the ICR to 
maintain allelic expression (Smilinich et al. 1999). Kcnq1ot1 expression on the 
paternal allele is functionally linked to silencing of 8-10 genes in cis (Mancini-
Dinardo et al. 2006). Genes near the Kcnq1ot1 promoter (Kcnq1, Cdkn1C, Slc22a18, 
Phlda2) are imprinted in the embryo and placenta in mice and humans. In contrast, 
genes located farther away from the promoter (Ascl2, Cd81, Tssc4, Osbpl5) are 
imprinted only in the placenta (Fig. 3.1). Kcnq1ot1 maintains imprinting of both 
ubiquitously imprinted and placental-specific imprinted genes through DNA 
methylation at the ICR and repressive histone methylation (Lewis et al. 2004; 
Mohammad et al. 2010). The ubiquitously imprinted genes are repressed on the 
paternal chromosome by DNA methylation at the DMR 610bp from TSS of Kcnq1ot1 
(Mohammad et al. 2010). Deletion of Dnmt1 or the DMR results in loss of imprinting 
of the ubiquitously imprinted genes in the embryo and the placenta (Lewis et al. 2004; 
Mohammad et al. 2010). However, imprinting of the placental specific genes is intact. 
Maintenance of imprinting of placental specific imprinted genes is proposed to involve 
repressive histone marks placed by epigenetic modifiers recruited by Kcnq1ot1 (Lewis 
et al. 2004).   
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Igf2 and Cdkn1C are expressed by the GlyTs (Redline et al. 1993; Georgiades et 
al. 2002) and Ascl2 and Phlda2 are expressed in the ectoplacental cone, during early 
development, but are later exclusively expressed by spongiotrophoblasts and 
syncytiotrophoblasts respectively (Guillemot et al. 1994; Frank et al. 1999; Oh-
McGinnis et al. 2011). IGF2P0-/- (placenta-specific) placentas and IGF2-/- (global) 
placentas display significantly reduced GlyTs (Constancia et al. 2002; Sferruzzi-Perri 
et al. 2011). Biallelic expression of Igf2 through the deletion of the H19 DMR also 
leads to an increase in GlyT number and placental glycogen (Esquiliano et al. 2009). 
Cdkn1c mouse mutants display abnormal GlyT progenitor differentiation accompanied 
by decreased glycogen in the placenta (Coan et al. 2006; Tunster et al. 2011). Phlda2-/- 
placentas have increased junctional zone volume (Tunster et al. 2010). Phlda2 
overexpression also results in abnormal GlyTs and reduced glycogen content in the 
placenta (Tunster et al. 2010). Biallelic expression of Phlda2 also affects junctional 
zone formation in the placenta (Salas et al. 2004). Ascl2-/- placentas are devoid of 
GlyTs (Oh-McGinnis et al. 2011). 
 
In zebrafish and mouse embryos, miR-126 modulates PI3K and MAPK signaling 
to control proliferation and migration of endothelial cells to modulate angiogenesis 
(Fish et al. 2008; Wang et al. 2008). miR-126 also regulates cell proliferation of colon 
and breast  cancer cells (Guo et al. 2008; Zhang et al. 2008; Zhou et al. 2013), and 
human hematopoietic stem cells (Lechman et al. 2012)  by targeting members of the 
PI3K and MAPK pathways. Based on the fact that miR-126 has perfect sequence 
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conservation, miR-126 potentially has a conserved role in regulating PI3K and MAPK 
pathways. 
 
To understand the mechanism through which miR-126 regulates GlyT 
development, gene expression of several imprinted genes implicated in GlyT and 
junctional zone development was analyzed. To minimize biases in gene expression 
from changes in cellular composition of the placenta, analyses were performed on 
E12.5 placentas, where there are no significant differences in junctional zone area. We 
show a dysregulation of imprinted gene expression in miR-126-/- placentas 
accompanied by changes in DNA methylation at ICRs and dysregulation of Dnmt1. 
PI3K and MAPK signaling pathways were also analyzed in the placenta. We show 
significantly reduced AKT and ERK signaling in miR-126-/- placentas. The results of 
this study identify potential signaling mechanisms through which miR-126 regulates 
junctional zone trophoblast development in the murine placenta. 
 
 
3.4 Results and discussion 
 
 
3.4.1 miR-126 regulates imprinted gene expression and DNA methylation at 
DMRs on chromosome 7 in the placenta 
 
To identify the molecular pathways through which miR-126 affects glycogen 
trophoblast expansion, expression levels of genes that are known regulators of GlyT 
development were analyzed. The Igf2 cluster contains the imprinted genes Igf2 and  
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Figure 3.1 Imprinted genes on the distal end of chromosome 7. Imprinted genes on 
chromosome 7 are organized into two clusters. The distal end contains genes Igf2, 
H19 and Ins2, regulated by the imprint control center IC1. Binding of insulator CTCF 
proteins at IC1 DMR activates H19 expression on the maternal chromosome. 
Methylation of IC1 on the paternal chromosome prevents CTCF binding and activates 
Igf2 expression. The second cluster containing 8-10 genes regulated by IC2 DMR 
(KvDMR1). LncRNA Kcnq1ot1 suppresses genes in cis on the paternal chromosome. 
Methylation of IC2 on the maternal chromosome turns-off Kcnq1ot1 expression. 
Genes closer to IC2 are ubiquitously imprinted in the embryo and the placenta. Genes 
further away from IC2 DMR are imprinted only in the mouse placenta. 
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H19 and Ins2. Deletion of Igf2 or H19 results in altered glycogen trophoblast numbers 
(Lopez et al. 1996; Esquiliano et al. 2009). The Kcnq1ot1 cluster contains Cdkn1c 
(p57Kip2), Phlda2, Kcnq1, Ascl2, Ospbl5, Cd81 and Tssc4. Loss of Cdkn1c leads to 
glycogen trophoblast differentiation defects (Tunster et al. 2011). Phlda2 deletion 
results in spongiotrophoblast hypertrophy and increased JZ area (Tunster et al. 2010). 
Ascl2 hypomorphs have reduced spongiotrophoblasts and no GlyTs (Oh-McGinnis et 
al. 2011). 
 
We analyzed expression levels of the imprinted genes implicated in JZ and GlyT 
development located in these two clusters in E12.5 placentas (n=4) by qRT-PCR (Fig. 
3.3). miR-126-/- placentas show significantly reduced expression of Igf2 and 
significantly elevated H19 expression (Fig. 3.2A) when compared to miR-126+/+ 
placentas. However, Igf2 and H19 expression is unchanged between miR-126-/- and 
miR-126+/+ embryos (Fig. 3.4A).  
 
We next investigated if aberrant imprinted gene expression is associated with changes 
in DNA methylation at imprinted loci. DNA methylation at IC1 and IC2 from 
genomic DNA isolated from E12.5 miR-126-/- and miR-126+/+ (n=2) littermate 
placentas was analyzed by pyrosequencing. At the IC1 locus, CTCF insulator proteins 
cooperatively bind to the DMR to maintain imprinting. miR-126-/- placentas display 
significantly increased methylation at several CpGs of the DMR corresponding to 
CTCF target sites 3 and 4 (-2.9kb to -1.7kb from H19 TSS) (Fig. 3.2B), but is 
unchanged at DMRs corresponding to CTCF target sites 1 and 2 (-4.6kb to -3.5kb 
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from H19 TSS) (Fig. 3.2C). Deletions of CTCF sites in tandem have highlighted their 
role in maintaining imprinting at this locus. Previous studies have shown that deletion 
of three CTCF target sites (sites 2,3,4) results in a reactivation of H19 and loss of Igf2 
expression on the paternal allele and a reciprocal effect on the maternal allele 
(Thorvaldsen et al. 1998; Thorvaldsen et al. 2002). A mouse model carrying deletion 
of CTCF target sites 2 and 3 displays changes in pup weights and loss of imprinting in 
this region (Ideraabdullah et al. 2014). Mice with mutations in CTCF target site 4 
alone also display loss of imprinting in endodermal and mesodermal tissues (Pant et 
al. 2004). Together, these data suggest that changes in methylation at the CTCF target 
sites results in bi-allelic expression of Igf2 and H19 in miR-126-/- placentas at E12.5. 
 
We next investigated expression levels of imprinted genes in the IC2 cluster. 
Expression of imprinted genes in this cluster is controlled by transcription of the long 
non-coding RNA Kcnq1ot1 that runs antisense to Kcnq1. miR-126-/- placentas have 
significantly reduced expression of Kcnq1ot1 and no significant difference in Kcnq1 
expression (Fig. 3.3A). Expression of Cdkn1c is significantly reduced, whereas Phlda2 
expression levels were unaffected in miR-126-/- placentas at E12.5 (Fig. 3.3A). 
Expression of Kcnq1ot1, Cdkn1c and Phlda2 were unchanged between miR-126-/- and 
miR-126+/+ embryos (Fig. 3.4B). At the IC2 locus, a DMR adjacent to transcriptional 
start site (TSS) of Kcnq1ot1 regulates imprinting of genes close to the cluster. There 
were no significant differences in methylation levels of the CpGs at IC2 (Fig. 3.3B). 
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Figure 3.2 miR-126 regulates imprinted gene expression and DNA methylation at 
the H19/Igf2 imprinting cluster in the placenta. Gene expression levels of 
maternally imprinted gene Igf2 and paternally imprinted gene H19 in E12.5 placentas 
by quantitative RT PCR (n=3, from two litters for each genotype). Error bars indicate 
SEM. (** p≤0.01) (A). Percent methylation of CpGs at CTCF binding site 3 of imprint 
control center IC1 (B). Percent methylation of CpGs at CTCF binding site 4 of imprint 
control center IC1 (C). Percent methylation of CpGs at CTCF binding site 1 of imprint 
control center IC1 (D). Percent methylation of CpGs at CTCF binding site 2 of imprint 
control center IC1 (E). 
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We next investigated if imprinted genes in other genomic locations are also 
dysregulated in miR-126-/- placentas. Peg3 is an imprinted gene located in the 
centromeric region of chromosome 7 that regulates transcription of several placental-
specific gene families (Kim et al. 2013). Grb10 is an imprinted gene on chromosome 
11 whose deletion leads to placental defects and IUGR in embryos (Charalambous et 
al. 2010). Expression levels of both Peg3 and Grb10 are significantly downregulated 
in miR-126-/- placentas at E12.5 (Fig. 3.3C). Global DNA methylation levels in E12.5 
placentas were tested by DNA dot blot assay with an anti-5methyl cytosine antibody. 
miR-126-/- placentas display reduced methylation when compared to miR-126+/+ 
littermate placentas (Fig. 3.3D).These results indicate that loss of miR-126 results in a 
global dysregulation of methylation and imprinted gene expression in the placenta but 
not in the embryo. 
 
3.4.2 miR-126 regulates Dnmt1 expression in the placenta and trophoblast stem 
cells 
 
Deletion of the DNA maintenance methylase, Dnmt1, results in aberrant imprinted 
gene expression in the placenta (Lewis et al. 2004; Weaver et al. 2010). We 
investigated if dysregulation Dnmt1 was the cause for global changes in DNA 
methylation and imprinted gene expression observed in miR-126-/- placentas. 
Interestingly, Dnmt1 expression was significantly dysregulated at the mRNA and 
protein levels in miR-126-/- placentas at several developmental stages analyzed. Dnmt1  
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Figure 3.3 miR-126 regulates imprinted gene expression and DNA methylation in 
the placenta at E12.5. Gene expression levels of maternally imprinted gene Kcnq1ot1 
and paternally imprinted genes Kcnq1, Cdkn1C and Phlda2 in E12.5 placentas by 
quantitative RT PCR (n=3, from two litters for each genotype). Error bars indicate 
SEM. (* p≤0.05) (** p≤0.01) (A). Percent methylation of CpGs at Kcnq1ot1 imprint 
control center (B). Gene expression levels of imprinted genes Grb10 and Peg3 in 
E12.5 placentas by quantitative RT PCR (n=3, from two litters for each genotype). 
Error bars indicate SEM. (* p≤0.05) (** p≤0.01) (C). DNA dot blot using an anti-
5methyl cytosine antibody on total genomic DNA (250, 100, 50ng) from miR-126+/+ 
and miR-126-/- placentas (n =3, from two litters for each genotype) (D). 
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Figure 3.4 miR-126-/- embryos do not display changes in expression of imprinted 
genes and Dnmt1. Gene expression levels of maternally imprinted gene Igf2 and 
paternally imprinted gene H19 in E12.5 embryos by quantitative RT PCR (n=3, from 
two litters for each genotype). Error bars indicate SEM (A). Gene expression levels of 
maternally imprinted gene Kcnq1ot1 and paternally imprinted genes Cdkn1C and 
Phlda2 in E12.5 embryos by quantitative RT PCR (n=3, from two litters for each 
genotype). Error bars indicate SEM (B). Gene expression levels of Dnmt1 in E12.5 
embryos and placentas by quantitative RT PCR (n =3, from two litters for each 
genotype) (C) 
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mRNA expression level in miR-126-/- placentas is significantly increased at E10.5, 
significantly reduced at E12.5 and unchanged at E15.5 when compared to miR-126+/+ 
placentas (Fig. 3.5A). At the protein level, DNMT1 expression in miR-126-/- placentas 
is reduced at E10.5, unchanged at E12.5 and reduced at E15.5 (Fig. 3.5B). miR-126-/- 
placentas at E12.5 also displayed significantly reduced expression of Dnmt3a, but no 
significant change in expression levels of Dnmt3b, Tet1, Tet2 and Tet3 (Figure 
3.6A,B). We also observed upregulation of Dnmt1 expression in miR-126-/- 
trophoblast stem cells that did not reach significance (Fig. 3.5C).  
 
 Collectively, these data suggest that miR-126 controls Dnmt1 expression in a 
dynamic manner in the trophoblasts of the placenta at the transcriptional and the post-
translational level to regulate DNA methylation and glycogen trophoblast 
development. 
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Figure 3.5 miR-126 regulates Dnmt1 expression in the placenta and trophoblast 
stem cells. Gene expression levels of Dnmt1 in E10.5, E12.5 and E15.5 placentas by 
quantitative RT PCR (n =3, from two litters for each genotype) (A). Western blot 
analysis and quantification of protein expression by optical density of tissue lysates 
from E10.5, E12.5 and E15.5 placentas. Membranes were probed with antibodies 
against DNMT1 and GAPDH (loading control) (n = 2, from two litters for each 
genotype, quantification from two independent experiments) (B). Gene expression 
levels of Dnmt1 in miR-126-/- and miR-126+/+ trophoblast stem cells (TSC) by 
quantitative RT PCR (n =3, from two litters for each genotype) (C). 
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3.4.3 miR-126 regulates AKT and ERK signaling in the placenta 
 
In endothelial cells of the developing embryo, miR-126 modulates angiogenesis by 
binding to and degrading inhibitors of the PI3K and MAPK signaling pathways (Fish 
et al. 2008; Wang et al. 2008). Akt1-/- embryos and placentas display growth 
impairment in utero (Yang et al. 2003; Kent et al. 2012) and Akt1-/- placentas have 
severely reduced glycogen trophoblasts (Kent et al. 2012). PI3K and MAPK signaling 
was investigated in E12.5 and E15.5 placentas. miR-126-/- placental lysates displayed 
reduced pAKT and pERK expression at E12.5 when compared to miR-126+/+ 
littermates (Fig. 3.7A,B). Interestingly, miR-126-/- placentas also display significantly 
increased AKT1 expression (Fig. 3.7A). There is no significant difference in pAKT, 
AKT1 and pERK expression in placentas at E15.5 (Fig. 3.7A,B). Glycogen synthase 
kinase-3 (GSK 3) is a regulator of glycogen synthesis and is negatively regulated by 
PI3K-mediated activation of AKT. There were no significant differences in expression 
levels of pGSK3β and GSK3β in miR-126-/- placentas at E12.5 or E15.5 when 
compared to miR-126+/+ littermates (Fig. 3.7C). 
 
To identify potential direct targets of miR-126 in the placenta, expression 
levels of genes that are validated targets of miR-126 in other cell types (Spred1, 
Vcam1, Egfl7, Pik3r2, CrkII) were analyzed. miR-126 inhibits translation of Spred1, 
Vcam1 and Pik3r2 in endothelial cells (Fish et al. 2008; Harris et al. 2008; Wang et al. 
2008) and Eglf7 in lung cancer cells (Sun et al. 2010). Paradoxically, expression levels 
of Spred1 were significantly reduced in miR-126-/- placentas (Fig. 3.7D). There was 
	 74	
no significant difference in expression levels of Vcam1, Egfl7 (Fig. 3.7D) and Pik3r2 
(Fig. 3.7 E) in miR-126-/- placentas. miR-126 has been shown to regulate HSC 
proliferation by inhibiting CrkII expression (Lechman et al. 2012). CRKII, an adaptor 
protein for PI3K signaling was significantly up regulated in miR-126-/- placentas at 
E12.5 and E15.5 (Fig. 3.7E). 
 
Discussion 
 
The distal portion of mouse chromosome 7 contains several imprinted genes (Igf2, 
H19, Kcnq1ot1, Cdkn1c, Phlda2, Ascl2) that are organized into two distinct, 
independently regulated clusters. Gain and loss-of function mutants of these imprinted 
genes, as well as mutants with bi-allelic gene expression, display defects in glycogen 
cell proliferation and differentiation (Constancia et al. 2002; Salas et al. 2004; 
Esquiliano et al. 2009; Tunster et al. 2010; Oh-McGinnis et al. 2011; Sferruzzi-Perri et 
al. 2011; Tunster et al. 2011), similar to the phenotypes observed in miR-126-/- 
placentas. miR-126-/- placentas display aberrant expression of Igf2, H19, Cdkn1c, 
Ascl2, Phlda2 and Kcnq11ot1 at E12.5 accompanied by changes in DNA methylation 
at some CpGs of imprint control centers. 
The absence of more robust changes in DNA methylation at both imprinted loci 
could potentially be due to contaminating cell types with biallelic expression of 
imprinted genes. Although some imprinted genes are known to be expressed by GlyTs 
(Igf2, Cdkn1C), a detailed analysis of imprinting has not been performed in all of the 
trophoblast cell subtypes of the placenta. Recent evidence also suggests that the  
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Figure 3.6 Gene expression analyses of regulators of DNA methylation. Gene  
expression levels Dnmt3a and Dnmt3b in E12.5 placentas by quantitative RT PCR 
(n=3, from two litters for each genotype). Error bars indicate SEM. (* p≤0.05) (A). 
Gene expression levels Tet1, Tet2 and Tet3 in E12.5 placentas by quantitative RT PCR 
(n=3, from two litters for each genotype). Error bars indicate SEM (B). Western blot 
analysis of tissue lysates from E12.5 placentas. Membranes were probed with 
antibodies against p53 and GAPDH (loading control) (C).  Gene expression levels 
E2f1, E2f3 and Retinoblastoma (Rb) in E12.5 placentas by quantitative RT PCR (n=3, 
from two litters for each genotype). Error bars indicate SEM. (* p≤0.05) (D). 
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Figure 3.7 miR-126 regulates PI3K and MAPK pathways in the placenta. Western 
blot analysis and quantification of protein expression in tissue lysates by optical 
density from E12.5 and E15.5 placentas. Membranes were probed with antibodies 
against pAKT and AKT1 (A). Western blot analysis and quantification of protein 
expression in tissue lysates by optical density from E12.5 and E15.5 placentas. 
Membranes were probed with antibodies against pERK and ERK1/2 (B). Western blot 
analysis and quantification of protein expression in tissue lysates by optical density 
from E12.5 and E15.5 placentas. Membranes were probed with antibodies against 
pGSKβ and GSK3β (C). Gene expression levels of Spred1, Vcam1 and Egfl7 in E12.5 
placentas by quantitative RT PCR (n =3, from two litters for each genotype) (D). 
Western blot analysis of tissue lysates from E12.5 and E15.5 placentas. Membranes 
were probed with antibodies against PIK3R2, CRKII and GAPDH (loading control) 
(E). 
 
 
 
	 77	
junctional zone is hypomethylated when compared to the fetal labyrinth (Decato et al. 
2017). Future studies that trace maintenance of imprinting in the placenta throughout 
development will elucidate the cell types and developmental windows in which 
imprinting is maintained in the placenta. 
 
Our analysis suggested that miR-126 broadly regulates DNA methylation in the 
placenta by modulating Dnmt1 expression. Dnmt1 regulates allele specific expression 
of imprinted genes by maintaining methylation at DMRs (Li et al. 1993; Howell et al. 
2001). DNMT1 methylates newly synthesized hemi-methylated DNA during the S 
phase in dividing cells (Li et al. 1993). Additionally, Dnmt1 loss of function mutants 
die around E10.5, and as a consequence studies focusing on LOI have utilized 
placental tissue from E9.5. At mid-gestation, GlyT progenitors undergo a rapid, 250-
fold expansion and form tight clusters of mature GlyTs by E14.5 (Coan et al. 2006). 
We speculate that reduced Dnmt1 expression in miR-126-/- placentas at E12.5 leads to 
a failure in maintaining allele specific expression of imprinted genes resulting in 
aberrant increase of GlyT number. Imprinted genes regulating GlyT development 
potentially have major roles during mid and late gestation in the placenta. However, 
studying imprinting and DNA methylation in mid and late gestation placentas are 
challenging due to the lack of techniques that can trace allelic expression in tissues. 
 
Dnmt1 is regulated at the transcriptional and post-translational levels by several 
proteins (Lin and Wang 2014; Scott et al. 2014). Based on the absence of canonical 
binding sites for miR-126 in the Dnmt1 3’UTR, we surmise that miR-126 regulates 
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Dnmt1 expression indirectly and in a placenta-restricted manner. Furthermore, the 
dynamic dysregulation of Dnmt1 transcripts and protein along with aberrant signaling 
of proteins that regulate Dnmt1 expression suggest that miR-126 modulates Dnmt1 
expression at both the transcriptional and post-translational level. 
 
miR-126 has a conserved function in regulating PI3K and MAPK signaling. miR-
126 modulates PI3K and MAPK signaling in mouse endothelial cells, human 
hematopoietic stem cells, colorectal and breast cancers by blocking translation of 
inhibitors of AKT and ERK signaling. miR-126 potentially inhibits trophoblast 
specific factors that downregulate AKT and ERK signaling in the placenta. 
 
 
3.5 Materials and methods 
 
 
Real Time RT-PCR  
Embryos and placentas (E12.5) were isolated in cold PBS and flash frozen in liquid 
nitrogen. RNA was isolated using Trizol (Invitrogen) and reverse transcribed using 
SuperScript II (Quanta Biosciences). Gene expression was measured quantitatively 
using PerfeCTa SYBR Green SuperMix for iQ (Quanta Biosciences). Primer sets are 
listed in the table below. Differences in target gene expression was quantified using 
the ∆∆CT method and normalized to ß-actin and 18S rRNA. 
Gene Forward Primer (5’ –> 3’) Reverse primer (5’ –> 3) 
Igf2 AGCAATCGGAAGTGAGCAAAC GGATGGAACCTGATGGAAACG 
H19 GGCTCCCAGAACCCACAAC GGGTTTTGTGTCCGGATTCA 
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p57 GCCGGGTGATGAGCTGGGAA AGAGAGGCTGGTCCTTCAGC 
Phlda2 CCCGCCAAGGAGCTGTTT CCTTGTAATAGTTGGTGACGATGGT 
Kcnq1 CAAAGACCGTGGCAGTAAC CCTTCATTGCTGGCTACAAC 
Kcnq1ot1 GGTCTGAGGTAGGGATCAGG GGCACACGGTATGAGAAAAGATTG 
Dnmt1 CCTAGTTCCGTGGCTACGAGGAGAA TCTCTCTCCTCTGCAGCCGACTCA 
Grb10 AGGATCATCAAGCAACAAGGTCTC ATTACTCTGGCTGTCACGAAGGA 
Peg3 ATGCCCACTCCGTCAGCG GCTCATCCTTGTGAACTTTG 
E2f1 GCCCTTGACTATCACTTTGGTCTC CCTTCCCATTTTGGTCTGCTC 
E2f3 GCCTCTACACCACGCCACAAG TCGCCCAGTTCCAGCCTT C 
Rb ACTCCGTTTTCATGCAGAGACTAA GAGGAATGTGAGGTATTGGTGACA 
Spred1 GCCAAGTCAGCCAGATACCAT AGGGACCCTAGTTTGGGACTT 
Vcam1 GGGACCACATCTACGCTGACA CCTGTCTGCATCCTCCAGAAA 
Egfl7 ATGAGACCATGTGGGGCTC GGTCTCCGAGATGGAACCTCCG 
18s rRNA AACCCGTTGAACCCCATT CCATCCAATCGGTAGTAGCG 
 
DNA dot blot assay 
Genomic DNA was isolated from E12.5 placentas with phenol and diluted to various 
concentrations. DNA was denatured with 5µl of 0.1M NaOH, cooled down on ice, 
neutralized with 1µl of 6.6M-ammonium acetate. 1µl from each DNA dilution was 
spotted on a nitrocellulose membrane (Immobilon-NY) and air-dried. The membrane 
was then UV-crosslinked for 5min at 220nm, blocked with 5% milk in TBST for 1 
hour and probed with an antibody against 5-methyl cytosine (Cell Signaling). After 
washing with TBST, the membrane was incubated with [HRP]-conjugated anti-rabbit 
(1:10000) antibody. Proteins were visualized using ECL Plus (G.E). 
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Pyrosequencing assay 
Bisulphite conversion was performed on genomic DNA isolated from decidua free 
E12.5 placentas. DMRs at the H19 and Kcnq1ot1 loci was amplified with specific 
primers and sequencing performed to identify methylated CpGs. Biulphite conversion, 
amplification and sequencing was performed by EpigenDx, Inc. 
 
Generation of trophoblast stem cells 
Trophoblast stem cells were isolated using the method of Tanaka et al. from 
blastocysts derived from timed mating of miR-126+/- mice (Tanaka et al. 1998). TSCs 
were cultured without feeders in 30% TS medium containing RPMI 1640, 20% heat-
inactivated fetal bovine serum, 1% sodium pyruvate, 1% penicillin-streptomycin, 1% 
glutamine, and 100 µM β-mercaptoethanol and 70% conditioned medium isolated 
from irradiated primary mouse embryonic fibroblasts (MEFs) cultured in TS medium. 
 
Western blot analysis 
Protein was isolated from placentas using radioimmunoprecipitation assay (RIPA) 
buffer containing a cocktail of protease and phosphatase inhibitors (Sigma). Tissue 
lysates were mixed with 5x NuPage loading buffer and heated at 700C for 10min. 
20µg of proteins were fractionated on a 4-12% gradient gel and transferred to a 
nitrocellulose membrane (Bio-Rad). The membrane was blocked in 5% nonfat milk in 
TBST (0.1% Tween 20 in 1X Tris-buffered saline) and probed with antibodies against 
DNMT1 (Cell Signaling), pAKT (Santa Cruz), AKT (Santa Cruz), pERK (Santa 
Cruz), ERK (Santa Cruz), pGSK3b (Cell Signaling) GSK3b (Santa Cruz), p53 (Santa 
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Cruz), PIK3R2 (Santa Cruz), CRK(R&D), GAPDH (Santa Cruz). After washing with 
TBST, the membrane was incubated with [HRP]-conjugated anti-rabbit (1:10000). 
The proteins were visualized using ECL Plus (G.E). 
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Chapter 4: miR-126 regulates glucose homeostasis 
 
4.1 Rationale 
 
Diabetes is a complex metabolic disorder that manifests from a combination of 
multiple genetic and environmental factors. Complications from Type-2 diabetes 
mellitus (T2DM) can cause stroke, hypertension, renal failure and myocardial 
infarction, which is one of the leading causes of morbidity and mortality worldwide. 
Increased healthcare costs and loss of productivity associated with diabetes in the US 
has been estimated to be 245 billion USD in 2012 (American Diabetes 2013). Even 
though diabetes is one of the oldest diseases know to man, the underlying disease 
mechanism is still incompletely understood and to date a cure is has been elusive. To 
develop new therapies and improve the efficacy of current treatments, it is critical to 
develop a thorough understanding of the mechanisms that play a role in the 
development and progression of diabetes. Mouse models of diabetes have reduced 
expression levels of miR-126 (Liang et al. 2013) and plasma from type 2 diabetes 
patients has reduced circulating miR-126 (Zampetaki et al. 2010; Mocharla et al. 
2013; Zhang et al. 2015). However, a causative role for miR-126 in T2DM has not 
been established. Understanding of a possible causative role for miR-126 in T2DM 
will give us novel insight into the genetic basis for the development of diabetes. 
 
4.2 Abstract 
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Diabetes is a chronic metabolic disease that is the major cause of stroke, 
hypertension, renal failure and myocardial infarction. There is substantial evidence to 
suggest that genetic mutations can increase susceptibility to insulin resistance and 
insulin secretion deficiencies leading to T2DM. We show that loss of a single copy of 
miR-126 results in fasting hyperglycemia in male and female mice, accompanied by 
reduced levels of serum insulin. miR-126+/- male but not female mice also display 
glucose intolerance. A fraction of miR-126+/- male mice also display reduced weight-
gain after birth. This data highlights a possible causative role for miR-126 in 
metabolic dysfunction. 
 
4.3 Introduction 
 
Diabetes is a chronic metabolic disease whose incidence has been increasing 
dramatically over the past few decades. T2DM is the more prevalent form with an 
estimated 552 million people worldwide expected to have the disease in 2030 
(Whiting et al. 2011). T2DM is characterized by hyperglycemia resulting from 
peripheral organs developing insulin resistance, leading to hyperinsulinemia, and 
eventually beta cell failure. Importantly T2DM often leads to major pathologies of the 
cardiovascular system like atherosclerosis resulting from increased breakdown of 
lipids for energy needs. Poorly managed diabetes is the major cause of stroke, 
hypertension, renal failure and myocardial infarction. A high-calorie diet and 
sedentary lifestyle is one of the major causes for the development of obesity and 
T2DM. There is also substantial evidence to suggest that genetic mutations can 
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increase susceptibility to insulin resistance and insulin secretion deficiencies leading 
to T2DM. In support, a high concordance rate in monozygotic twins (Kaprio et al. 
1992; Matsuda and Kuzuya 1994) and increased prevalence in offspring of affected 
patients has been reported (Rich 1990). There are over 40 inheritable genetic variants 
shown to increase susceptibility to diabetes (Polonsky 2012). 
 
MicroRNAs are a class of evolutionary conserved, non-coding RNAs that 
repress gene expression post-transcriptionally by targeting the 3’untranslated region 
(3’UTR) of mRNAs. Multiple microRNAs (miRNAs) have physiological roles in 
regulating beta cell function (Poy et al. 2004; Joglekar et al. 2009), adipocyte 
differentiation (Karbiener et al. 2009), and homeostasis in other tissues affected by 
T2DM (Li et al. 2009; Shan et al. 2010). Although several studies show associations 
between altered miRNA expression and development of T2DM, few studies have 
focused on elucidating a possible role for miRNAs in the pathogenesis of the disease 
(Fernandez-Valverde et al. 2011; Kantharidis et al. 2011). 
 
miR-126 is an evolutionarily conserved endothelial miRNA embedded in 
intron 7 of Egfl7 (Campagnolo et al. 2005; Schmidt et al. 2007; Nikolic et al. 2013). 
Egfl7 is a largely endothelial cell-restricted gene that encodes a secreted protein that 
binds to extracellular matrix components (Campagnolo et al. 2005; Schmidt et al. 
2007; Nikolic et al. 2013). miR-126 has a conserved role in regulating PI3K and 
MAPK pathways. miR-126 regulates cell proliferation of colon (Zhou et al. 2013) and 
breast (Zhang et al. 2008) cancers by targeting members of the PI3K pathway. 
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Mutations in genes regulated by the PI3K/AKT pathway are known to be associated 
with hereditary forms of diabetes (Winter and Silverstein 2000; Wang et al. 2002). 
Mouse models of diabetes have reduced expression levels of miR-126 (Liang et al. 
2013) and plasma from type 2 diabetes patients has reduced circulating miR-126 
(Zampetaki et al. 2010; Mocharla et al. 2013; Zhang et al. 2015). However, a causative 
role for miR-126 in T2DM has not been established.  
 
4.4 Results and discussion 
 
4.4.1 miR-126+/- mice display fasting hyperglycemia and hypoinsulinemia 
 
To examine if miR-126 regulates glucose metabolism, we analyzed glucose and 
insulin levels of 10-12 weeks old miR-126+/- mice, as miR-126-/- mice in a congenic 
C57Bl6/J die in utero. We analyzed fasting blood glucose of female miR-126+/-  
(n=11) and miR-126+/+ (n=12) mice, 4hrs after food withdrawal using a glucometer. 
miR-126+/- male and female mice display significantly elevated levels of fasting blood 
glucose when compared to miR-126+/+ littermates (Fig. 4.1A). We also measured 
levels of fasting serum insulin from these mice using an ELISA assay. miR-126+/- 
male (n=7) and female mice (n=3) display a reduction in serum insulin levels 
compared to miR-126+/+ mice without reaching statistical significance (Fig. 4.1B). 
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Figure 4.1 miR-126+/- mice display fasting hyperglycemia and hypoinsulinemia. 
Fasting blood glucose levels of 10-12 week old male and female miR-126+/- mice (4hr 
fast). Error bars indicate SEM. (* p≤0.05)  (A). Fasting serum insulin levels of 10-12 
week old male and female miR-126+/- mice measured by ELISA (4hr fast) (B). 
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4.4.2 miR-126+/- mice are glucose intolerant and insulin sensitive 
 
We next tested glucose and insulin sensitivity in these mice by performing 
glucose and insulin tolerance tests. For the glucose tolerance test, after a 4-hour fast, 
10-12 weeks old male and female mice were injected with glucose (1g/kg) intra 
peritoneally and blood glucose levels were measured at 15, 30, 45, 60 and 120 minutes 
after the injection. miR-126+/- male mice (n=7) display significantly elevated blood 
glucose levels at several time points after the glucose injection when compared to 
miR-126+/+ mice (n=7)  (Fig. 4.2A). Glucose tolerance test was quantified by area 
under the curve (Fig. 4.2B). In contrast, there was no significant difference in glucose 
sensitivity in miR-126+/- female mice (Fig. 4.2C,D). Glucose intolerance in miR-126+/- 
mice potentially results from insulin resistance in the peripheral organs and/or 
defective insulin secretion in the pancreas. To test if miR-126+/- were insulin resistant, 
insulin tolerance test was performed. After a 4-hour fast, 10-12 weeks old male and 
female mice were injected with human insulin (1U/kg) intra peritoneally and blood 
glucose levels were measured at 15, 30, 45, 60 and 120 minutes after the injection. 
miR-126+/-male (Fig 4.3A,B) and female mice (Fig 4.3 C, D) do not display 
significant differences in blood glucose levels when compared to miR-126+/+ mice at 
all time points after the insulin injection. This data demonstrates that miR-126+/- male 
mice are glucose intolerant and miR-126+/- male and female mice are insulin sensitive. 
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Figure 4.2 miR-126+/- male, but not female mice display glucose intolerance. 
Glucose tolerance test (1g/kg) in 10-12 week old male mice after a 4hr fast. Error bars 
indicate SEM. (* p≤0.05)  (** p≤0.01) (A). Area under the curve (AUC) from glucose 
tolerance test on male mice. Error bars indicate SEM. (** p≤0.01) (B). Glucose 
tolerance test (1g/kg) in 10-12 week old female mice after a 4hr fast Error bars 
indicate SEM. (* p≤0.05) (C). Area under the curve (AUC) from glucose tolerance 
test on female mice. Error bars indicate SEM (D). 
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Figure 4.3 miR-126+/- male and female mice are insulin sensitive. Insulin tolerance 
test (1U/kg) in 10-12 week old male mice after a 4hr fast Error bars indicate SEM (A). 
Area under the curve (AUC) from insulin tolerance test on male mice. Error bars 
indicate SEM (B). Insulin tolerance test in 10-12 week old female mice (1U/kg) after a 
4hr fast Error bars indicate SEM. (* p≤0.05) (C). Area under the curve (AUC) from 
insulin tolerance test on female mice. Error bars indicate SEM (D). 
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4.4.3 miR-126+/- male mice display sporadic weight defects 
 
We also measured weights of mice starting at five weeks of age. A fraction of 
male miR-126+/- mice (20-30%) display sporadic weight defects (Fig. 4.4A). However, 
the reduced weight phenotype is not completely penetrant in male miR-126+/- mice 
(Fig. 4.4A). In contrast, female miR-126+/- mice do not display weight gain defects 
(Fig. 4.4B). 
 
Discussion 
 
 Several genetic and environmental factors have been shown to be important 
determinants of T2DM. Several genome wide association studies have identified 
multiple genes that make individuals susceptible to T2DM (Yasuda et al. 2008; Voight 
et al. 2010; Yamauchi et al. 2010). However, the mechanisms through which these 
genes contribute to the pathogenesis of the disease are not completely understood. 
Panels of miRNAs have been identified as potential markers of T2DM (He et al. 
2017), however, there are no reports on the functions of individual miRNAs in the 
pathogenesis of the disease. 
 
 It is quite striking that loss of a single copy of miR-126 is sufficient to induce 
T2DM-like symptoms in an inbred mouse strain. Male and female miR-126+/- mice  
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Figure 4.4 miR-126+/- male but not female mice display weight-gain defects. 
Mouse weights of male miR-126+/+ (n = 12) and miR-126+/- (n = 4, abnormal weight. n 
= 8, regular weight) mice starting at 5 weeks of age. Error bars indicate SEM. (*** 
p≤0.001) (A). Mouse weights of female miR-126+/+ and miR-126+/- starting at 5 weeks 
of age. Error bars indicate SEM (B). 
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display fasting hyperglycemia and hypoinsulinemia. This strongly suggests that 
reduced miR-126 levels not only correlate with, but also are functionally important for 
controlling blood glucose levels. Interestingly, only male miR-126+/- mice are severely 
glucose intolerant, and both male and female miR-126+/- mice are insulin sensitive. 
Sex specific differences in the phenotypes could potentially arise from a protective 
effect of estrogen on pancreatic beta cell failure in female mice (Liu and Mauvais-
Jarvis 2010). This data suggests that loss of miR-126 may lead to a defective glucose 
stimulated insulin response. Future studies will focus on identifying novel expression 
domains for miR-126 in the pancreas and other peripheral organs associated with 
T2DM. Functional studies on pancreatic beta cells from miR-126+/- mice will help 
characterize insulin secretion defects in these mice. 
 
4.5 Materials and methods 
 
Measurement of fasting blood glucose and serum insulin. 
10-12 weeks old mice were placed in fresh cage without chow for 4 hours. Blood 
glucose levels were measured using AlphaTrak2 glucometer with blood drawn from 
the tail vein of mice. For serum isolation, blood from the tail vein was allowed to 
coagulate at room temperature for 30min and spun at 2500g for 15min at 4C. 
Supernatant was collected and stored at -800C. Insulin levels were measured using an 
insulin ELISA kit (R&D). 
 
Glucose and insulin tolerance tests 
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10-12 week old mice, after a 4-hour fast, were injected with either 1g/kg of glucose or 
1U/kg of human insulin intra-peritoneally. Blood glucose levels were measured every 
15min for 2hrs using AlphaTrak2 glucometer. 
 
Mouse weights 
Mouse weights were recorded every week on the same day starting at 5 weeks using a 
standard weighing scale. 
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Chapter 5: Conclusions and future perspectives 
 
5.1 Summary 
 
miR-126 has a functional role in regulating glycogen trophoblast proliferation 
in the murine placenta and glucose metabolism in adult mice in a C57Bl6\J 
background. In Chapter2, using a miR-126 loss of function mouse model, I have 
demonstrated that deletion of miR-126 results in aberrant glycogen trophoblast 
proliferation in the placenta and IUGR of embryos. In chapter 3, as a potential 
mechanism for regulating glycogen trophoblasts, I have shown that miR-126 regulates 
DNA methylation and imprinted gene expression in placenta by regulating DNMT1 
expression. In chapter 4, I have shown that loss of a single copy of miR-126 can result 
in fasting hyperglycemia, glucose intolerance and sporadic weight defects in adult 
male mice. Results form this study provides insights into the role of miR-126 in 
placental development and metabolic dysfunction. 
 
5.2 Implications of miR-126 signaling in placental development 
 
The placenta is indispensable during development and despite several disease 
pathologies associated with the placenta, human placental development has not been 
extensively studied. Research on human placentas mainly relies on post partum tissue 
or choriocarcinoma cell lines. The use of transgenic mouse models has greatly aided 
identification of several genes and pathways that regulate human placental 
development. Research on miRNAs in placental development has been restricted to 
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studying their roles in in vitro and ex vivo trophoblast cultures or as biomarkers in 
placental pathologies. A large majority of miRNA knockout mice have subtle or no 
phenotypes and analysis of their placentas are largely ignored. miR-126 is one of the 
very few miRNAs with a lethal loss-of-function phenotype. Using a miR-126-/- mouse 
model, the studies described in chapters 2 and 3 give an insight into the role of miR-
126 in placental development. 
 
miR-126 deletion results in aberrant imprinted gene expression, methylation 
changes at ICRs and dysregulation of glycogen trophoblasts. However, there is no 
direct evidence to demonstrate loss of imprinting in miR-126-/- placentas. Assays used 
to quantify allele specific expression of imprinted genes rely on the presence of 
parent-specific single nucleotide polymorphisms (SNPs). Since miR-126-/- mice are in 
a congenic background, future studies will involve crossing miR-126-/- mice into a 
Mus castaneus mouse line. miR-126-/- placentas from miR-126+/- Mus musculus and 
Mus castaneus intercrosses will be used to quantify expression levels of imprinted 
genes from musculus and castaneus alleles and determine if deletion of miR-126 
results in loss of imprinting in the placenta. 
 
miR-126-/- embryos display pervasive hemorrhaging, reduced numbers of 
proliferating endothelial cells and defective angiogenesis as previously reported 
(Kuhnert et al. 2008; Wang et al. 2008). We hypothesized that loss of miR-126 would 
also result in deficient angiogenesis in the placenta. Surprisingly, miR-126-/- placentas 
have no defects in numbers of proliferating endothelial cells and vascular coverage in 
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the fetal labyrinth. However, miR-126-/- placentas display increased numbers of 
glycogen trophoblasts in the junctional zone. We have also identified a novel 
expression domain for miR-126 in trophoblast stem cells and all the differentiated 
trophoblast subtypes in the placenta. This data suggests that the junctional zone 
phenotypes in miR-126-/- placentas are cell autonomous. However, this does not 
eliminate the possibility that, endothelial cells of miR-126-/- placentas act in cell non-
autonomous ways to affect trophoblasts. To delineate the role of miR-126 in junctional 
zone trophoblasts and endothelial cells, future experiments will use a conditional 
deletion of miR-126 (miR126fl/fl). Endothelial specific deletion of miR-126 will be 
done by crossing miR126fl/fl and VE Cadherin-Cre mice (Alva et al. 2006). To study 
the role of miR-126 specifically in the junctional zone trophoblasts of the placenta, 
future experiments will use utilize miR-126fl/fl and Tpbpa-Cre (Simmons et al. 2007) 
mouse lines. miR126fl/fl mice will also be used to investigate if defects in the embryo 
contribute to placental phenotypes. To test if the loss of miR-126 in the embryo 
contributes to phenotypes of the extraembryonic tissues, Mox-2-Cre (MORE) mice 
(Tallquist and Soriano 2000) will be used to delete miR-126 specifically in the 
epiblast. 
 
Both Egfl7 and miR-126 are expressed by trophoblasts of the placenta and 
endothelial cells of the placenta and embryo (Fitch et al. 2004; Lacko et al. 2014). 
EGFL7 and miR-126 loss-of-function mutants display complementary phenotypes in 
endothelial cells of the embryo and placenta during development. Global loss of 
EGFL7 does not result in major vascular defects in the embryo, whereas global loss of 
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miR-126 results in pervasive vascular defects in the embryo. In the placenta, loss of 
EGFL7 results in constricted vessels and aberrant vascular patterning, whereas loss of 
miR-126 results in no major vascular defects in the placenta. It is plausible, that 
redundant pathways exist for functions performed by Egfl7 (Rossi et al. 2015), but not 
miR-126 in the embryonic vasculature, and redundant pathways exist for functions 
performed by miR-126 but not Egfl7 in the placental vasculature. Egfl7 is a secreted 
protein, and could potentially have autocrine and paracrine effects, whereas miR-126 
would mostly have intercellular functions. It is plausible that both vascular beds use 
distinct molecular mechanisms during angiogenesis. This result may also reflect the 
fact that the endothelial cell lineage in the fetal labyrinth is derived from the 
extraembryonic mesoderm of the allantois whereas all embryonic and adult 
endothelial cells are derived from the mesoderm of the embryo proper. The 
transcriptome of the placental endothelium is unique when compared to that of other 
vascular beds (Nolan et al. 2013). 
 
Intronic miRNAs are proposed to have an antagonistic or synergistic effect on 
the function of the host gene. Egfl7 expression is unaffected in miR-126-/- embryos 
and placentas, and 3’UTR of EGFL7 does not contain binding sites for miR-126.	Any	synergistic	or	antagonistic	roles	of	miR-126	on	Egfl7	signaling	would	be	through	indirect	mechanisms.	
 
Future experiments will identify intersecting pathways between Egfl7 and 
miR-126 signaling. Gene expression analysis comparing embryonic and placental 
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vasculature from both Egfl7-/- and miR-126-/- mice will provide insights into 
overlapping and unique pathways regulated by Egfl7 and miR-126 during 
developmental angiogenesis in both vascular beds. Similarly gene expression analysis 
on Egfl7-/- and miR-126-/- trophoblast stem cells and their differentiated progenitors 
will be used to identify overlapping and unique pathways in trophoblasts. 
 
miR-126 is proposed to be generated from alternatively spliced Egfl7 
transcripts (Wang et al. 2008). The promoter of Egfl7, and intron 7, where miR-126 is 
located, contain multiple conserved CpG islands (Fig. 5.1). Epigenetic therapies on 
human cancer cell lines have been shown to modulate Egfl7 and miR-126 expression 
(Saito et al. 2009). Our data from the murine placenta indicate that miR-126 controls 
imprinted gene expression in part by regulating Dnmt1 expression. Recent evidence 
suggests that Dnmt1 is imprinted in the human placenta (Das et al. 2013). It is 
plausible that DNA methylation of Egfl7 promoter and intron 7 regulates biogenesis of 
miR-126. Future experiments will explore the possibility of an autoregulatory loop 
between DNMT1 and miR-126 (Model in Fig 5.1) 
 
Assisted reproductive technology (ART) has been associated with increased 
incidences of imprinting disorders in humans, potentially resulting in long-term 
adverse health outcomes in offspring (Odom and Segars 2010; Eroglu and Layman 
2012; Chiba et al. 2013). In mouse models, ART procedures including superovulation, 
embryo transfer and culture of fertilized blastocysts cumulatively increase DNA 
methylation defects, loss of imprinting and morphological abnormalities in the 
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placenta (de Waal et al. 2014; de Waal et al. 2015). These studies also highlight the 
increased susceptibility of the placenta to methylation defects after ART procedures. It 
is not clear what culture conditions and mechanisms make the trophoblasts in the 
blastocyst vulnerable to methylation defects. We have shown that miR-126 regulates 
DNA methylation specifically in the trophoblasts of the placenta and more 
importantly, trophoblast stem cells, but not the embryo. It is plausible that 
environmental insults and cues trigger a miR-126 dependent DNA methylation 
response. Future experiments will identify upstream signaling factors that are part of 
the machinery controlling DNA methylation through miR-126 in trophoblasts. 
 
5.3 Implications of miR-126 signaling in glucose metabolism 
 
Type-2 diabetes is a chronic metabolic disorder that manifests from a 
combination of environmental and genetic factors. Although several studies show 
associations between altered miRNA expression and development of T2DM, few 
studies have focused on elucidating a possible role for miRNAs in the pathogenesis of 
the disease (Fernandez-Valverde et al. 2011; Kantharidis et al. 2011). Strikingly, loss 
of even a single copy of miR-126 leads to fasting hyperglycemia, hypoinsulinemia and 
severe glucose intolerance. To our knowledge this is the first example in which 
haploinsufficiency in a single miRNA results in metabolic dysfunction. 
 
Collectively, data from the metabolic studies suggests that miR-126+/- mice 
have a defective insulin response. Future studies will involve functional assays on  
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Figure 5.1 Putative model for miR-126 in the placenta and pancreas. miR-126 
controls glycogen trophoblast numbers in the placenta by regulating DNA methylation 
and imprinted gene expression. miR-126 potentially regulates pancreatic beta cell 
function by regulating genomic imprinting at the Kcnq1 locus. (MODY – Maturity 
Onset Diabetes of the Young). 
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isolated pancreatic islets from these mice to identify any defects in insulin secretion. 
To measure islet response to glucose stimulation in vivo, a hyperglycemic clamp will 
be used. Islets isolated from miR-126+/- and miR-126+/+ will also be used to perform ex 
vivo glucose stimulated insulin secretion assays. 
 
A number of rare autosomal dominant, monogenic forms of diabetes termed 
maturity onset diabetes (MODY) have been identified in humans. Fourteen MODY 
subtypes are listed by the Online Mendelian Inheritance in Man (OMIM) database, 
four of which account for 80–90% of diagnosed cases (Shields et al. 2010). Of 
particular importance for our experiments, is the identification of Kcnq1 imprinted 
cluster as a susceptibility locus (Travers et al. 2013). Kcnq1 mutations in humans that 
cause loss of imprinting of CDKN1C on the paternal allele result in early onset 
diabetes accompanied by growth restriction (Kerns et al. 2014). Mouse models have 
demonstrated that deletion of Kcnq1 has no effect on mice, but loss of imprinting in 
that region results in reduced pancreatic beta cell mass and onset of diabetes (Asahara 
et al. 2015). Since miR-126 regulates CDKN1C expression by regulating DNA 
methylation in the placenta, it is plausible that miR-126 performs similar roles in the 
pancreas. Future experiments will analyze pancreatic islets isolated from miR-126+/- 
mice to identify potential defects in beta cell mass and imprinting. 
 
The functional role of glycogen trophoblasts in the placenta is not known. It 
has been speculated that these cells provide nutrition to the embryo during late 
gestation, when energy demands become high. Importantly, studies in mice have 
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shown that the development and differentiation of this cell type is intricately liked to 
imprinted gene expression in the placenta. In human placentas, abnormal glycogen 
deposition is observed in pregnancies with gestational diabetes. Women treated with 
insulin have similar glycogen content to healthy women whereas women with a diet-
based intervention have abnormal glycogen content in the placenta (Desoye et al. 
1992; Desoye et al. 2002). This suggests that placenta serves as a buffer for excess 
fetal glucose during gestation. Increased placental glycogen in miR-126-/- placentas 
could potentially arise from a combination of pancreatic defects in pregnant miR-
126+/- mice, resulting in hyperglycemia, and the inability of miR-126-/- placentas to 
buffer excess glucose. To test maternal contribution to placental phenotypes, 
blastocysts from miR-126+/- intercrosses will be transferred to miR-126+/+ and miR-
126+/- mice. 
 
5.4 Conclusions 
 
 
The studies presented in my thesis have used a loss-of-function mouse model 
to elucidate a miR-126 specific role in placental development and glucose metabolism. 
miR-126 regulates extra embryonic energy stores and DNA methylation specifically in 
the placenta. These findings uncover a novel mechanism for miRNA-based regulation 
of DNA methylation in extra embryonic tissue and raise the possibility of using miR-
126 as a marker for non-invasive detection imprinting disorders. Furthermore, its role 
in regulating glucose metabolism may provide a novel angle for therapeutic targeting 
to treat insulin secretion defects in diabetes. Future studies on the roles of miR-126 in 
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placental development and glucose metabolism will determine its potential uses as a 
biomarker and as a therapeutic agent. 
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